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people from Cloning and Expression Unit and Purification Unit in Novartis Siena 
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purified the large bacterial libraries used in chapter 2. In a similar way, the work of the 
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Foundation) in San Diego (CA) was essential to provide such a large number of human 
recombinant proteins used in both chapter 2 and 3. Within the thesis you will also see 
several experiments performed using label-free technologies with a constant exchange of 
ideas, suggestions and opinions with Dr. Werner Pansegrau and Dr. Paola Lo Surdo from 
Biophysical characterization Unit in Novartis Siena and Dr. Hendrick Wuensche from Pall 
bioscience. A particular acknowledgment also to Dr Vincenzo Nardi Dei for technical 
assistance in DLS measurements, Alessia Liguori (PhD student) for providing protein 
constructs used in chapter 3 and Barbara Benucci (PhD student) for plasmid production 
used for cell transfection in FACS experiments.  
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Abstract 
 
Adhesion, immune evasion and invasion are key determinants during bacterial pathogenesis. 
Pathogenic bacteria, indeed, possess a wide variety of surface exposed and secreted 
proteins which allow them to adhere to tissues, escape the immune system and spread 
throughout the human body. Therefore, extensive contacts and a broad crosstalk between 
the human and the bacterial extracellular proteomes take place at the host-pathogen 
interface at the protein level. Recent researches emphasized the importance, from a 
therapeutic point of view, of a global and deeper understanding of the molecular mechanisms 
which underlie bacterial immune evasion and pathogenesis. Through the use of a large-
scale, unbiased, protein microarray-based approach and of wide libraries of human and 
bacterial purified proteins, novel host-pathogen interactions were identified. A scheme of this 
approach can be found on page xviii. 
This approach was first applied to Staphylococcus aureus (chapter two of this thesis), a 
human commensal gram-positive bacterium also cause of a wide variety of diseases ranging 
from skin infections to endocarditis and sepsis. The screening led to the identification of 
several novel interactions between the human and the S. aureus extracellular proteomes. 
Among all, the interaction between the S. aureus immune evasion protein FLIPr (formyl-
peptide receptor like-1 inhibitory protein) and the human complement component C1q, key 
players of the offense-defense fighting, was characterized using label-free techniques and 
functional assays. 
The same approach was also applied to Neisseria meningitidis (chapter three of this thesis), 
a gram-negative encapsulated bacterium major cause of bacterial meningitis and fulminant 
sepsis worldwide. The screening led to the identification of several potential human receptors 
for the neisserial adhesin A (NadA), an important adhesion protein and key determinant of 
meningococcal interactions with the human host at various stages. The interaction between 
NadA and human LOX-1 (low-density oxidized lipoprotein receptor) was confirmed using 
label-free technologies and cell binding experiments in vitro.  
Taken together, these two examples provided not only concrete insights into S. aureus and 
N. meningitidis pathogenesis, but also identified protein microarray coupled with appropriate 
validation methodologies as a powerful large scale tool for host-pathogen interactions 
studies. 
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Aim of the thesis 
 
Pathogenic bacteria express on the surface and secrete a wide variety of proteins that 
specifically mediate their adhesion, evasion and invasion into the host body. These contacts 
occur extensively at the host-pathogen interface between the bacterial and host extracellular 
proteomes. Usually, bacterial immune evasion molecules and all the surface-exposed 
molecules constitute excellent vaccine antigens. Therefore, the identification and 
characterization of novel host-pathogen interactions are essential for both the understanding 
of molecular mechanism of pathogenesis, and for therapeutic purposes. The large number of 
interactions discovered so far, sometimes promiscuous and involving multiple components of 
the human defense apparatus, seems to suggest a very complex picture where additional 
interactions may take place at the host-pathogen interface. Aim of this study is to apply an 
un-biased systematic large scale protein microarray-based approach to identify novel 
interactions between bacterial and the human extracellular proteomes. 
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 Introduction 
Every day, a real molecular battle between pathogenic bacteria and their hosts take place. 
Each of them exploits in toto their fully equipped molecular arsenal to finally be the survivor. 
Evading the assorted molecular attack of the host immune system constitutes a key feature 
for bacterial survival. Thus it is not surprising that bacteria evolved several mechanisms for 
host colonization, immune system evasion and host invasion. These crucial events are 
usually mediated by protein-protein interactions at the host-pathogen interface. Immune 
recognition and host colonization processes are characterized, in fact, by wide and extended 
interactions between the host and bacterial extracellular proteomes, constituted by all the 
surface exposed and secreted proteins that are the key determinants in the host-pathogen 
interplay. The co-evolution between host and bacterial pathogens led to the development of 
bacterial proteins able to recognize and exploit specific host receptors, enabling bacteria to 
adhere and penetrate into the host. In the same way, once entered, several proteins are 
specifically produced to counteract both the innate immune response, constituted by 
complement system and antimicrobial peptides, and cell-mediated response, mainly 
constituted by professional phagocytes such as neutrophils, monocytes and macrophages. 
Here is presented a detailed description of the human complement system, a key effector in 
bacterial recognition. In addition, the examples of Staphylococcus aureus and Neisseria 
meningitidis will be provided to describe the main strategies for complement evasion.  
The human complement system 
The human complement system is the main component of the innate immune response and 
accomplishes numerous functions like the recognition of foreign cells, activation of adaptive 
immunity and the removal of cellular debris [1]. It is thereby considered the first barrier 
against pathogenic bacteria and viruses that enter in the bloodstream. It is composed by 
more than 30 proteins present in human serum and tissue fluid as well as on cell surfaces [2, 
3]. The complement system is usually described as a double-edged sword, since it is very 
easily activated, but at the same time tightly regulated in each step. The immune system has 
in fact to keep a tight balance between attack on foreign surfaces and protection of host ones 
through the use of several regulators that prevent complement activation [4, 5]. From a 
molecular point of view, the complement system is characterized by serin-proteases that 
specifically cleave the next factor, constituting a proteolytic cascade resulting in bacterial 
opsonisation and lysis [6]. The complement action can be divided in three main steps: the 
initiation, the cascade amplification and the effector production. The initiation step is 
characterized by proteins able to recognize a wide variety of molecular substrates which lead 
to the activation of the first serine proteases. The complement cascade is then amplified: 
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 each serin-protease is activated by the previous and activates the next through a proteolytic 
cleavage [7, 8]. During the proteolytic cleavage several peptides called anaphylatoxin are 
generated. These constitute the effectors. They are able to trigger a wide variety of 
responses including inflammation, phagocytosis and B-cells and T-cells stimulation. Based 
on the type of molecules involved in the activation step, three different activation pathways 
can be distinguished: the classical, the lectin and the alternative pathways. All the three 
pathways converge at a central step, the cleavage of complement component C3.  
 
Figure 1.1 The complement cascade. Complement classical (A), lectin (B) and alternative (C) 
pathway are shown. Classical and lectin pathways converge in the cleavage by C1s and MASP of C4 
and C2 which constitutes the C3 convertase. The terminal pathway (D) with the formation of MAC is 
also shown.  
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 The classical pathway (CP) 
The initial step that triggers complement classical pathway activation is the recognition of 
non-self molecules by the complement component C1 (figure 1.1A). C1 is a 790 kDa 
complex formed by the association of a recognition protein, C1q, and a Ca2+-dependent 
tetramer composed by two copies of two proteases, C1r and C1s [9, 10]. C1q is a 450KDa 
multiprotein complex characterized by three subcomponents (C1qA, C1qB and C1qC) 
organized in heterotrimers, which are then super-organized to form an examer with a 
peculiar bouquet-like structure (figure 1.2A-B). The overall structure is characterized by an 
N-terminal collagen-like "stalk" and C-terminal globular heads (figure 1.3A) which are 
involved in the recognition function of C1q. C1q has the striking ability to recognize abnormal 
structures from self and the crystal structure of the globular heads provides a basis for its 
versatile recognition properties [11].  
 
Figure 1.2  Three-dimensional structural model of the human C1 complex. (A-B) Side and bottom 
view of the C1q molecule. The C1qA (blue), C1qB (green) and C1qC (red) subcomponents are shown. 
(C-D) Side and bottom view of the C1 complex. C1 is depicted in the resting state, in which C1q is 
proposed to have a ‘closed’ conformation. C1r and C1s are shown and interact with C1q collagen-like 
stalk 
Host-pathogen interactions at the protein level: an introduction Chapter ONE 
 
EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 5 
 
 Usually complement activation is associated with the recognition by C1q of aggregated 
antibodies or C-reactive protein (CRP). There is increasing evidence, however, that C1q 
possesses a broader range of recognition including b-amyloid fibrils [12, 13] the pathological 
form of the prion protein [14, 15] and apoptotic cells [16], consequently acting as a key factor 
in immune tolerance. Binding of C1q to a target cell or molecule is thought to elicit a signal 
that triggers self-activation of C1r, which converts proenzyme C1s into a highly specific serin-
protease that cleaves complement components 4 and 2 (C4 and C2), thereby activating the 
classical complement pathway. C1r and C1s have similar domain architectures, since they 
are characterized by five non-catalytic modules: the N-terminal CUB domain is followed by 
an epidermal growth factor (EGF)-like module, a second CUB domain and a tandem repeat 
of complement control protein (CCP) modules. The very C-terminal domain is the catalytic 
chymotrypsin-like SP (Serin-Protease) domain (figure 1.3B) [17]. Two copies of C1r and two 
of C1s associate with the C1q collagen-like stalk, folding into a compact ‘8-shaped’ 
conformation, enabling contact between the catalytic regions of C1r and C1s, a prerequisite 
for C1s activation [18] (figure 1.2C-D). 
 
Figure 1.3 Domain organization similarities between the classical and lectin pathways. (A) 
Domain prediction of the C1qA, C1qB and C1qC proteins compared with MBL and Ficolin I. Collagen 
domain (black), C1q globular head (grey), C-type lectin domain (CLECT - pink) and fibrinogen binding 
domain (FBG - violet) are shown. (B) Domain prediction of the C1r, C1s, MASP-1 and MASP-2 serine 
proteases. The six domains are shown: the N-terminal CUB domain (red), the epidermal growth factor 
(EGF)-like domain (dark green), a second CUB domain, a tandem repeat of complement control 
protein (CCP) modules (yellow) and the catalytic chymotrypsin-like serin protease domain (Tryp_SPc - 
light green) at the very C-term. Overall structure is also shown (adapted from Gal et al. 2006). Domain 
prediction was performed using SMART-EMBL online software (http://smart.embl-heidelberg.de) 
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 The lectin pathway (LP) 
The triggering point of the lectin pathway is, from a structural and functional point of view, 
very similar with the classical pathway. It is activated by many types of recognition molecules 
including mannose-binding lectin (MBL) [19] and ficolins (H, L and M-types also called type I, 
II and III) [20] which associates with MASP (MBL-Associated Serine Protease), resembling 
the C1q/C1r/C1s complex (figure 1.1B). MBL is, from a structural point of view, very similar 
to C1q, except that it is composed by only one type of polypeptide chain and it binds to 
pathogen-associated molecular patterns (PAMPs) on the surface of microbes (figure 1.4) 
[21, 22]. MBL is in fact characterized by a collagen-like region and a C-type carbohydrate 
recognition domain (CRD) at the C-terminal of the protein, able to recognize 
monosaccharides such as glucose, mannose and N-acetyl-glucosamine. In the same way, 
ficolins contain a short N-terminal, a collagen-like domain and a C-terminal fibrinogen-like 
domain (FBG) instead of the CRD domain as recognition portion (figure 1.3A) [23]. MASP-1, 
MASP-2 and MASP-3 form with C1r and  C1s the family of serine-proteases and share 
identical domain organization and similar overall structure (figure 1.3B). 
 
Figure 1.4 The assembled model of a MASP protease in complex with a tetramer of MBL 
trimers. MBL collagen stem and CRD domain are shown (orange). MASP dimer is also shown.   
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The C3 cleavage and the terminal pathway 
Both the classical and the lectin pathway, after the activation of the C1s and MASP serine 
proteases respectively, converge in a unique pathway which starts with the highly specific 
cleavage of complement components 2 and 4 (C2 and C4) (figure 1.1D). The resulting 
cleavage lead to the production of two C2 fragments, C2a and C2b, and two C4 fragments, 
C4a and C4b. In a spatiotemporal order, C4 is first cleaved by C1s or MASP, than C4b binds 
to C2, which is then cleaved in C2a and C2b. The fragments C2a and C4b remain 
complexed together to form the C4b2a complex, also known as C3 convertase. This 
molecule is in fact able to specifically cleave the complement component C3 in C3a and C3b, 
driving to pathway amplification. C3a, C2b and C4a are not involved in complement 
amplification but constitute the so-called anaphylatoxins, potent pro-infammatory molecules 
which target specific activator receptors on phagocytic cells.  
The C3b fragment, instead, constitute the key molecule for complement fixation and 
amplification. It is in fact able to bind extraneous surfaces (like bacteria) driving to cell 
opsonization. In addition, when present at high concentrations, C3b can also complex with 
C4b2a (C3 convertase) to form the C4b2a3b complex, also known as C5 convertase, since 
it's able to cleave complement component C5 into C5a and C5b, directly driving to terminal 
pathway activation [24-27]. C5b is a very unstable molecule which can be however stabilized 
by complement component C6. The C5b6 complex attracts complement component C7 and 
C8 yielding to the C5b678 complex. The proteins in this complex acquire a highly 
hydrophobic character and can insert into cell membranes generating pores of 10Å diameter. 
The binding of multiple copies of C9 to the C5b678 complex yields the final Membrane Attack 
Complex (MAC) with a diameter of around 70Å (figure 1.5) [28-32]. 
The alternative complement pathway (AP) 
 In addition to the classical and lectin, a third pathway called alternative pathway was also 
described (figure 1.1C). It is based on spontaneous cleavage of C3 in C3a and C3b naturally 
occurring in serum. C3b, once cleaved, can complex both with the C3 convertase (C4b2a) 
forming the C5 convetase (C4b2a3b) as described above, or with complement factor B, 
driving to alternative pathway activation. The factor B, once complexed with C3b to form the 
C3bB complex, is activated by factor D to form the C3bBb complex, a C3 convertase [8, 33, 
34]. Upon increasing production of C3b, it can bind C3bBb becoming C3bBb3b with C5 
convertase properties and the addition of complement factor P (or properdin) stabilizes the 
complex leading to terminal pathway activation [35].   
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Figure 1.5 Hypothetical model of the C9 pore. A model of MAC is shown. The model is derived 
from a ring of 18 monomers of C8. Single C8 is highlighted in blue.  
The complement regulators 
Since the complement system can be easily and rapidly activated through the triggering of 
molecules of the three pathways, it needs to be finely tuned and regulated. Therefore several 
membrane bound and soluble Regulators of Complement Activity (RCA) are exposed or 
secreted by host cell to prevent self-attack. Among the soluble regulators, complement factor 
H (CFH), complement factor I (CFI), C4 binding protein (C4BP) and vitronectin constitute the 
key effectors in complement regulation. CFH is constituted by 20 Short Complement 
Regulator (SCR) domains, each of length about 61 residues. It binds to the C3 convertase 
(C3bBb) driving to the displacement of factor Bb and to convertase inactivation [36-38]. CFI, 
instead cleaves C3b bound to CFH into C3c and C3d, preventing re-complexing of C3b and 
therefore convertase formation [39, 40]. C4BP instead acts on C4, accelerating the decay of 
the C3 convertase (C4b2a). In addition acts as a cofactor for complement factor I in C3 
cleavage [41-44]. Vitronectin (also called S-protein or serum spreading factor) is an important 
extracellular matrix molecule and inhibitor of the complement terminal complex. It can inhibit 
the terminal complement complex at various stages through the occupation of the membrane 
binding site of the C5b-7 complex to form SC5b-7 complex [45] and through the prevention of 
C9 polymerization and MAC complex formation [46]. 
The decay-accelerating factor (DAF or CD55), the membrane cofactor protein (MCP or 
CD46), the complement receptor type I (CR1 or CD35) and the complement receptor of the 
immunoglobulin superfamily (CRIg) constitute the most popular examples of membrane 
bound complement regulators. DAF is able to recognize C4b and C3b fragments preventing 
Host-pathogen interactions at the protein level: an introduction Chapter ONE 
 
EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 9 
 
 cleavage of respectively C2 and factor B, thus avoiding complement activation. It is 
expressed on the plasma membranes of all cell types that are in close contact with plasma 
complement proteins [47-51]. MCP binds to C3b and C4b and functions as a cofactor of 
complement factor I for their cleavage [52, 53]. 
Usually both soluble and membrane bound RCA consist of strings of Complement Control 
Protein (CCP) domains, which from a functional point of view, are the direct responsible for 
complement regulation [54]. Viruses and bacteria often express proteins with an overall 
structure similar to the CCP domains, mimicking the mechanisms of host protection. 
Bacterial pathogens have also evolved proteins that bind the soluble regulators, which 
prevents complement mediated cell lysis and phagocytosis.  
 
Bacterial immune adhesion and evasion: the 
Staphylococcus aureus and Neisseria meningitidis 
examples 
The bacterial adhesion, evasion and dissemination processes take place though extensive 
protein-protein interactions between the human and bacterial extracellular proteomes. 
Among these three, the evasion process requires specific proteins to counteract the host 
immune system. Several bacteria, in fact, produce proteins which target key effectors of the 
immune system. Staphylococcus aureus and Neisseria meningitidis among others represent 
peculiar example for complement evasion and common evasion strategies are already 
known and well described in literature. 
Mechanism of immune evasion 
Despite the wide variety of bacterial proteins targeting the large panel of human proteins 
involved in immunity, three main evasion approaches can be identified: the recruitment or 
mimicking of complement regulators, the inactivation by enzymatic degradation (proteolysis) 
and the modulation or inhibition of complement proteins by direct interactions (figure 1.6) 
[55]. The key determinants for self and non-self determination are the RCA present on cell 
surfaces. Several pathogens have found the way to stably bind RCA that circulates in human 
plasma therefore preventing the complement action [56]. This process is mediated by 
common structural features present on RCA, the short consensus repeat (SCR) domains 
(like the CCP domain previously described) that allow the same bacterial protein to recruit 
different host RCA. In addition some viral proteins were described to be structurally similar to 
RCA, closely mimicking their function [57, 58]. The degradation of complement components 
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into non-functional proteins is the main feature of several bacterial proteases which targets a 
wide variety of human substrates [59-62]. Furthermore, the bacterial acquisition and 
activation of host proteases is an additional alternative to the enzymatic attenuation of 
complement. Complement is a very finely tuned system where a small change in regulation 
can break the delicate balance and complement efficiency. Therefore, surprisingly, only few 
bacterial proteins have been identified to directly bind complement components, inhibiting its 
action. Most of the identified proteins have been discovered in S. aureus even if also B. 
burgdorferi, streptococci and human parasites as Schistosoma and Trypanosoma have been 
shown to produce complement inhibitors [63, 64]. 
 
Figure 1.6 Mechanisms of bacterial immune evasion. Three main strategies can be distinguished: 
the captuding or mimicking of complement regulators, the inactivation by cleavage (proteolysis) and 
the modulation or inhibition of complement proteins by direct interactions. (Picture from Lambris 2008) 
S. aureus and N. meningitidis, masters of complement evasion 
Staphylococcus aureus is a gram-positive bacterium and opportunistic pathogen living as 
commensal in human skin and nasal cavities in 20% of humans [65, 66]. S. aureus 
constitutes, from a molecular point of view, a prototype for the study of immune evasion 
strategies. Despite the invasion and colonization molecular bases were well established [67, 
68], novel mechanisms of immune evasion and the relative immune-evading molecules have 
been discovered and described only recently, drawing S. aureus as an intriguing model of 
host-pathogen interplay [59, 69-71]. Most of the identified evasion processes target the 
complement initiation, amplification and pro-inflammatory molecules, since S. aureus 
peptidoglycan-rich cell wall protect it from MAC formation and complement mediated cell-
lysis [72]. Several proteins, in fact, impairs initiation of the classical pathway. Staphylococcal 
protein A (SpA) is one of the extensively studied and characterized protein in S. aureus. This 
protein binds Fc portion of IgG preventing recognition by C1q and FcγR thereby preventing 
classical complement and macrophage activation respectively [73, 74]. Less characterized 
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 than SpA, but not less relevant in pathogenesis are the staphylococcal binder of 
immunoglobulin (Sbi) and superantigen-like 10 (SSL-10) proteins, able to bind IgG deposited 
on the surface of the bacterium [71, 75, 76]. In addition, S. aureus has developed a way to 
use host proteases to inhibit complement. This is the case of staphylokinase, which, through 
the recruitment and activation of plasmilogen in plasmin, a wide spectrum serine-protease, 
degrades circulating and surface bound C3 and human IgG, thereby reverting their 
opsonization effect [77, 78]. Several S. aureus proteins are capable of direct complement 
inhibition at C3 and C5 level. Efb (extracellular fibrinogen-binding protein) is able to bind C3b 
and inhibit opsonophagocytosis [79]. Through structural analysis, an Efb-homologous protein 
(Ehp) has been identified. It shares with Efb the ability to bind C3b inducing conformational 
changes which prevent complement amplification. Ehp however binds two C3b molecules 
simultaneously and possesses a greater complement inhibition capacity [80, 81]. SCIN 
(staphylococcal complement inhibitor) and its homologues proteins SCINB and SCINC 
stabilize and inhibit the C4b2a and C3bBb convertases. The structure of the SCIN-C3bBb 
complex has shown that SCIN sterically blocks the formation of the C3-C3bBb complex, 
preventing C3 cleavage [82-85]. SSL-7 (staphylococcal superantigen-like protein-7), instead, 
binds C5 with high affinity, resulting in complement terminal pathway inhibition [86]. In 
addition to these complement regulator proteins, S. aureus secretes a plethora of proteins 
acting on monocytes and neutrophils preventing their activation. CHIPS (chemotaxis 
inhibitory protein of S. aureus) is an antagonist of C5a receptor [87, 88]; SSL5 blocks both 
the interaction between the P-selectin glycoprotein ligand 1 and P-selectin and the activation 
of GPCRs preventing neutrophils extravasation [89]. Very recently, in addition, FLIPr (formyl 
peptide receptor like-1 inhibitory protein) and FLIPr-like proteins have been described to 
have immune evasion properties. These proteins were first identified as inhibitors of formyl-
peptide receptor (FPR) and formyl-peptide receptor like-1 (FPRL1), two chemoattractant 
receptors on neutrophyls [90, 91]. In further studies these proteins have been described as 
potent FcγR antagonist on macrophages showing their ability in preventing opsonization and 
phagocytosis [92]. 
Neisseria meningitidis is a gram-negative encapsulated bacterium carried asymptomatically 
in the nasopharynx of approximately 5–10% of the human population [93]. For still not 
completely understood reasons it may become pathogenic and can cause meningococcal 
meningitis and septicemia. The ability to evade the host immune system is mainly due to 
cellular structures like capsule and LOS and LPS (lipo-oligosaccharides and lipo-
polysaccharides) [94]. Capsule is made of repeating saccharide units which are used to 
divide N. meningitidis into 12 immunologically distinct groups among which A, B, C, W, X, 
and Y are the most virulent. From a functional point of view, the capsular structure prevents 
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complement deposition and complement-mediated bacterial killing [95]. Sialic acid on LOS 
and LPS, instead, is thought to mimic sialic acid on host cells and subvert the complement 
alternative pathway by enhancing interactions of CFH with surface bound C3b [96]. Despite 
these two non-proteinaceous structures N. meningitidis is able to recruit, through surface 
proteins, several complement regulators to block activation of complement at several key 
steps. Key virulence factors for N. meningitidis are fHbp (factor H binding protein) and NspA 
(neisserial surface protein A), two proteins exposed on the bacterial surface able to bind 
complement factor H and inhibit complement [97, 98]. Based on its amino acid sequence, 
fHbp is divided, into either three variant groups or two sub-families [99, 100]. fHbp is also 
part of the recently released 4 component meningococcal vaccine (4cMenB) against type B 
meningococcus [101, 102]. In addition to fHbp and NspA, several other proteins have been 
described to target complement regulators. PorA (porin A) is a membrane protein which 
binds to C4bp; however, strong binding occurred only under hypotonic conditions [103]. The 
phase variable protein Opc (opacity protein) and the meningococcal surface fibril (Msf also 
known as NhhA and Hsf) bind to vitronectin allowing the decrease in MAC deposition, 
enhancing resistance to complement mediated killing and the binding to human brain 
endothelial cells through the cell-binding RGD domain of vitronectin [104, 105].  
 
Concluding remarks 
Within the last decade, significant progress has been made in the understanding of the 
different aspects of bacterial pathogenesis, mainly thanks to important technologic advances 
like whole genome sequencing and bioinformatic approaches. Furthermore, in the last years, 
important findings have been made to further detail the description of both the human 
immune system mechanism of function and of the modulation of bacterial response to 
environmental stimuli. Despite that, there are still several gaps in our knowledge on how 
bacteria pass from being commensal harmless to highly virulent and life threatening 
organisms and we are only beginning to appreciate the layers of complexity of bacterial 
evasion mechanisms. Large-scale approaches in the molecular biology, immunology, 
epidemiology and bioinformatic fields, with the years to come will provide a more accurate 
and detailed picture of host-pathogen interactions. Among all, the discovery of novel host-
pathogen interactions at the protein level can provide not only specific functional information 
on bacterial determinants, but also novel insights for the discovery and development of 
potentially effective therapeutic compounds and vaccine candidates. 
  
Host-pathogen interactions at the protein level: an introduction Chapter ONE 
 
EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 13 
 
 References 
 
1. Carroll, M.V. and R.B. Sim, Complement in health and disease. Adv Drug Deliv Rev, 
2011. 63(12): p. 965-75. 
2. Walport, M.J., Complement. First of two parts. N Engl J Med, 2001. 344(14): p. 1058-
66. 
3. Walport, M.J., Complement. Second of two parts. N Engl J Med, 2001. 344(15): p. 
1140-4. 
4. Kirkitadze, M.D. and P.N. Barlow, Structure and flexibility of the multiple domain 
proteins that regulate complement activation. Immunol Rev, 2001. 180: p. 146-61. 
5. Zipfel, P.F., Complement and immune defense: from innate immunity to human 
diseases. Immunol Lett, 2009. 126(1-2): p. 1-7. 
6. Nonaka, M., Evolution of the complement system. Subcell Biochem, 2014. 80: p. 31-
43. 
7. Forneris, F., J. Wu, and P. Gros, The modular serine proteases of the complement 
cascade. Curr Opin Struct Biol, 2012. 22(3): p. 333-41. 
8. Gros, P., F.J. Milder, and B.J. Janssen, Complement driven by conformational 
changes. Nat Rev Immunol, 2008. 8(1): p. 48-58. 
9. Arlaud, G.J., et al., Structural biology of C1: dissection of a complex molecular 
machinery. Immunol Rev, 2001. 180: p. 136-45. 
10. Cooper, N.R., The classical complement pathway: activation and regulation of the first 
complement component. Adv Immunol, 1985. 37: p. 151-216. 
11. Gaboriaud, C., et al., The crystal structure of the globular head of complement protein 
C1q provides a basis for its versatile recognition properties. J Biol Chem, 2003. 
278(47): p. 46974-82. 
12. Rogers, J., et al., Complement activation by beta-amyloid in Alzheimer disease. Proc 
Natl Acad Sci U S A, 1992. 89(21): p. 10016-20. 
13. Tacnet-Delorme, P., S. Chevallier, and G.J. Arlaud, Beta-amyloid fibrils activate the 
C1 complex of complement under physiological conditions: evidence for a binding site 
for A beta on the C1q globular regions. J Immunol, 2001. 167(11): p. 6374-81. 
14. Klein, M.A., et al., Complement facilitates early prion pathogenesis. Nat Med, 2001. 
7(4): p. 488-92. 
15. Mabbott, N.A., et al., Temporary depletion of complement component C3 or genetic 
deficiency of C1q significantly delays onset of scrapie. Nat Med, 2001. 7(4): p. 485-7. 
16. Navratil, J.S., et al., The globular heads of C1q specifically recognize surface blebs of 
apoptotic vascular endothelial cells. J Immunol, 2001. 166(5): p. 3231-9. 
17. Gaboriaud, C., et al., Structure and activation of the C1 complex of complement: 
unraveling the puzzle. Trends Immunol, 2004. 25(7): p. 368-73. 
18. Arlaud, G.J., et al., Structural biology of the C1 complex of complement unveils the 
mechanisms of its activation and proteolytic activity. Mol Immunol, 2002. 39(7-8): p. 
383-94. 
19. Holmskov, U., S. Thiel, and J.C. Jensenius, Collections and ficolins: humoral lectins 
of the innate immune defense. Annu Rev Immunol, 2003. 21: p. 547-78. 
20. Matsushita, M. and T. Fujita, Ficolins and the lectin complement pathway. Immunol 
Rev, 2001. 180: p. 78-85. 
21. Gal, P., et al., Serine proteases of the classical and lectin pathways: similarities and 
differences. Immunobiology, 2007. 212(4-5): p. 267-77. 
Chapter ONE Bacterial immune evasion at the protein level: an introduction 
 
14 EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 
 
 
22. Vorup-Jensen, T., J.C. Jensenius, and S. Thiel, MASP-2, the C3 convertase 
generating protease of the MBLectin complement activating pathway. 
Immunobiology, 1998. 199(2): p. 348-57. 
23. Kjaer, T.R., S. Thiel, and G.R. Andersen, Toward a structure-based comprehension 
of the lectin pathway of complement. Mol Immunol, 2013. 56(3): p. 222-31. 
24. Arlaud, G.J., M.G. Colomb, and J. Gagnon, A functional model of the human C1 
complex Emergence of a functional model. Immunol Today, 1987. 8(4): p. 106-11. 
25. Porter, R.R. and K.B. Reid, The biochemistry of complement. Nature, 1978. 
275(5682): p. 699-704. 
26. Ziccardi, R.J. and N.R. Cooper, Direct demonstration and quantitation of the first 
complement component in human serum. Science, 1978. 199(4333): p. 1080-2. 
27. Gaboriaud, C., et al., Deciphering the fine details of c1 assembly and activation 
mechanisms: "mission impossible"? Front Immunol, 2014. 5: p. 565. 
28. Muller-Eberhard, H.J., The membrane attack complex of complement. Annu Rev 
Immunol, 1986. 4: p. 503-28. 
29. Tschopp, J., H.J. Muller-Eberhard, and E.R. Podack, Formation of transmembrane 
tubules by spontaneous polymerization of the hydrophilic complement protein C9. 
Nature, 1982. 298(5874): p. 534-8. 
30. Tschopp, J., Ultrastructure of the membrane attack complex of complement. 
Heterogeneity of the complex caused by different degree of C9 polymerization. J Biol 
Chem, 1984. 259(12): p. 7857-63. 
31. DiScipio, R.G. and T.E. Hugli, The architecture of complement component C9 and 
poly(C9). J Biol Chem, 1985. 260(27): p. 14802-9. 
32. Hadders, M.A., D.X. Beringer, and P. Gros, Structure of C8alpha-MACPF reveals 
mechanism of membrane attack in complement immune defense. Science, 2007. 
317(5844): p. 1552-4. 
33. Pangburn, M.K. and H.J. Muller-Eberhard, The C3 convertase of the alternative 
pathway of human complement. Enzymic properties of the bimolecular proteinase. 
Biochem J, 1986. 235(3): p. 723-30. 
34. Xu, Y., S.V. Narayana, and J.E. Volanakis, Structural biology of the alternative 
pathway convertase. Immunol Rev, 2001. 180: p. 123-35. 
35. Forneris, F., et al., Structures of C3b in complex with factors B and D give insight into 
complement convertase formation. Science, 2010. 330(6012): p. 1816-20. 
36. Pangburn, M.K., R.D. Schreiber, and H.J. Muller-Eberhard, Human complement C3b 
inactivator: isolation, characterization, and demonstration of an absolute requirement 
for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med, 
1977. 146(1): p. 257-70. 
37. Vik, D.P., et al., Factor H. Curr Top Microbiol Immunol, 1990. 153: p. 147-62. 
38. Barlow, P.N., G.S. Hageman, and S.M. Lea, Complement factor H: using atomic 
resolution structure to illuminate disease mechanisms. Adv Exp Med Biol, 2008. 632: 
p. 117-42. 
39. Roversi, P., et al., Structural basis for complement factor I control and its disease-
associated sequence polymorphisms. Proc Natl Acad Sci U S A, 2011. 108(31): p. 
12839-44. 
40. Nilsson, S.C., et al., Complement factor I in health and disease. Mol Immunol, 2011. 
48(14): p. 1611-20. 
41. Hillarp, A. and B. Dahlback, The protein S-binding site localized to the central core of 
C4b-binding protein. J Biol Chem, 1987. 262(23): p. 11300-7. 
Host-pathogen interactions at the protein level: an introduction Chapter ONE 
 
EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 15 
 
 42. Hofmeyer, T., et al., Arranged sevenfold: structural insights into the C-terminal 
oligomerization domain of human C4b-binding protein. J Mol Biol, 2013. 425(8): p. 
1302-17. 
43. Nagasawa, S., et al., Human C4b-binding protein, C4bp. Chymotryptic cleavage and 
location of the 48 kDa active fragment within C4bp. FEBS Lett, 1983. 164(1): p. 135-
8. 
44. Blom, A.M. and S. Ram, Contribution of interactions between complement inhibitor 
C4b-binding protein and pathogens to their ability to establish infection with particular 
emphasis on Neisseria gonorrhoeae. Vaccine, 2008. 26 Suppl 8: p. I49-55. 
45. Preissner, K.T., R. Wassmuth, and G. Muller-Berghaus, Physicochemical 
characterization of human S-protein and its function in the blood coagulation system. 
Biochem J, 1985. 231(2): p. 349-55. 
46. Podack, E.R., K.T. Preissner, and H.J. Muller-Eberhard, Inhibition of C9 
polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol 
Microbiol Immunol Scand Suppl, 1984. 284: p. 89-96. 
47. Post, T.W., et al., Structure of the gene for human complement protein decay 
accelerating factor. J Immunol, 1990. 144(2): p. 740-4. 
48. Lublin, D.M. and J.P. Atkinson, Decay-accelerating factor: biochemistry, molecular 
biology, and function. Annu Rev Immunol, 1989. 7: p. 35-58. 
49. Holers, V.M., et al., Human C3b- and C4b-regulatory proteins: a new multi-gene 
family. Immunol Today, 1985. 6(6): p. 188-92. 
50. Law, S.K., C3 receptors on macrophages. J Cell Sci Suppl, 1988. 9: p. 67-97. 
51. Sim, R.B., et al., Structure and specificity of complement receptors. Immunol Lett, 
1987. 14(3): p. 183-90. 
52. Adams, E.M., et al., Contribution of the repeating domains of membrane cofactor 
protein (CD46) of the complement system to ligand binding and cofactor activity. J 
Immunol, 1991. 147(9): p. 3005-11. 
53. Liszewski, M.K. and J.P. Atkinson, Membrane cofactor protein. Curr Top Microbiol 
Immunol, 1992. 178: p. 45-60. 
54. Serruto, D., et al., Molecular mechanisms of complement evasion: learning from 
staphylococci and meningococci. Nat Rev Microbiol, 2010. 8(6): p. 393-9. 
55. Lambris, J.D., D. Ricklin, and B.V. Geisbrecht, Complement evasion by human 
pathogens. Nat Rev Microbiol, 2008. 6(2): p. 132-42. 
56. Zipfel, P.F., R. Wurzner, and C. Skerka, Complement evasion of pathogens: common 
strategies are shared by diverse organisms. Mol Immunol, 2007. 44(16): p. 3850-7. 
57. McKenzie, R., et al., Regulation of complement activity by vaccinia virus complement-
control protein. J Infect Dis, 1992. 166(6): p. 1245-50. 
58. Rosengard, A.M., et al., Variola virus immune evasion design: expression of a highly 
efficient inhibitor of human complement. Proc Natl Acad Sci U S A, 2002. 99(13): p. 
8808-13. 
59. Rooijakkers, S.H. and J.A. van Strijp, Bacterial complement evasion. Mol Immunol, 
2007. 44(1-3): p. 23-32. 
60. Oda, T., et al., Inactivation of chemotactic activity of C5a by the serratial 56-kilodalton 
protease. Infect Immun, 1990. 58(5): p. 1269-72. 
61. Chmouryguina, I., et al., Conservation of the C5a peptidase genes in group A and B 
streptococci. Infect Immun, 1996. 64(7): p. 2387-90. 
Chapter ONE Bacterial immune evasion at the protein level: an introduction 
 
16 EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 
 
 
62. Tsao, N., et al., Streptococcal pyrogenic exotoxin B cleaves properdin and inhibits 
complement-mediated opsonophagocytosis. Biochem Biophys Res Commun, 2006. 
339(3): p. 779-84. 
63. Inal, J.M. and R.B. Sim, A Schistosoma protein, Sh-TOR, is a novel inhibitor of 
complement which binds human C2. FEBS Lett, 2000. 470(2): p. 131-4. 
64. Deng, J., et al., Inhibition of the complement membrane attack complex by 
Schistosoma mansoni paramyosin. Infect Immun, 2003. 71(11): p. 6402-10. 
65. Peacock, S.J., I. de Silva, and F.D. Lowy, What determines nasal carriage of 
Staphylococcus aureus? Trends Microbiol, 2001. 9(12): p. 605-10. 
66. Lowy, F.D., Staphylococcus aureus infections. N Engl J Med, 1998. 339(8): p. 520-
32. 
67. Patti, J.M., et al., MSCRAMM-mediated adherence of microorganisms to host tissues. 
Annu Rev Microbiol, 1994. 48: p. 585-617. 
68. Foster, T.J. and M. Hook, Surface protein adhesins of Staphylococcus aureus. 
Trends Microbiol, 1998. 6(12): p. 484-8. 
69. Chavakis, T., K.T. Preissner, and M. Herrmann, The anti-inflammatory activities of 
Staphylococcus aureus. Trends Immunol, 2007. 28(9): p. 408-18. 
70. Foster, T.J., Immune evasion by staphylococci. Nat Rev Microbiol, 2005. 3(12): p. 
948-58. 
71. Rooijakkers, S.H., K.P. van Kessel, and J.A. van Strijp, Staphylococcal innate 
immune evasion. Trends Microbiol, 2005. 13(12): p. 596-601. 
72. Frank, M.M., Annihilating host defense. Nat Med, 2001. 7(12): p. 1285-6. 
73. Cedergren, L., et al., Mutational analysis of the interaction between staphylococcal 
protein A and human IgG1. Protein Eng, 1993. 6(4): p. 441-8. 
74. Gouda, H., et al., Three-dimensional solution structure of the B domain of 
staphylococcal protein A: comparisons of the solution and crystal structures. 
Biochemistry, 1992. 31(40): p. 9665-72. 
75. Zhang, L., et al., A second IgG-binding protein in Staphylococcus aureus. 
Microbiology, 1998. 144 ( Pt 4): p. 985-91. 
76. Itoh, S., et al., Staphylococcal superantigen-like protein 10 (SSL10) binds to human 
immunoglobulin G (IgG) and inhibits complement activation via the classical pathway. 
Mol Immunol, 2010. 47(4): p. 932-8. 
77. Lahteenmaki, K., P. Kuusela, and T.K. Korhonen, Bacterial plasminogen activators 
and receptors. FEMS Microbiol Rev, 2001. 25(5): p. 531-52. 
78. Rooijakkers, S.H., et al., Anti-opsonic properties of staphylokinase. Microbes Infect, 
2005. 7(3): p. 476-84. 
79. Lee, L.Y., et al., Inhibition of complement activation by a secreted Staphylococcus 
aureus protein. J Infect Dis, 2004. 190(3): p. 571-9. 
80. Hammel, M., et al., A structural basis for complement inhibition by Staphylococcus 
aureus. Nat Immunol, 2007. 8(4): p. 430-7. 
81. Hammel, M., et al., Characterization of Ehp, a secreted complement inhibitory protein 
from Staphylococcus aureus. J Biol Chem, 2007. 282(41): p. 30051-61. 
82. Katschke, K.J., Jr., et al., Structural and functional analysis of a C3b-specific antibody 
that selectively inhibits the alternative pathway of complement. J Biol Chem, 2009. 
284(16): p. 10473-9. 
83. Janssen, B.J., et al., Structure of compstatin in complex with complement component 
C3c reveals a new mechanism of complement inhibition. J Biol Chem, 2007. 282(40): 
p. 29241-7. 
Host-pathogen interactions at the protein level: an introduction Chapter ONE 
 
EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 17 
 
 84. Rooijakkers, S.H., et al., Structural and functional implications of the alternative 
complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat 
Immunol, 2009. 10(7): p. 721-7. 
85. Rooijakkers, S.H., et al., Immune evasion by a staphylococcal complement inhibitor 
that acts on C3 convertases. Nat Immunol, 2005. 6(9): p. 920-7. 
86. Langley, R., et al., The staphylococcal superantigen-like protein 7 binds IgA and 
complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J 
Immunol, 2005. 174(5): p. 2926-33. 
87. de Haas, C.J., et al., Chemotaxis inhibitory protein of Staphylococcus aureus, a 
bacterial antiinflammatory agent. J Exp Med, 2004. 199(5): p. 687-95. 
88. Postma, B., et al., Chemotaxis inhibitory protein of Staphylococcus aureus binds 
specifically to the C5a and formylated peptide receptor. J Immunol, 2004. 172(11): p. 
6994-7001. 
89. Bestebroer, J., et al., Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits 
P-selectin-mediated neutrophil rolling. Blood, 2007. 109(7): p. 2936-43. 
90. Prat, C., et al., A new staphylococcal anti-inflammatory protein that antagonizes the 
formyl peptide receptor-like 1. J Immunol, 2006. 177(11): p. 8017-26. 
91. Prat, C., et al., A homolog of formyl peptide receptor-like 1 (FPRL1) inhibitor from 
Staphylococcus aureus (FPRL1 inhibitory protein) that inhibits FPRL1 and FPR. J 
Immunol, 2009. 183(10): p. 6569-78. 
92. Stemerding, A.M., et al., Staphylococcus aureus formyl peptide receptor-like 1 
inhibitor (FLIPr) and its homologue FLIPr-like are potent FcgammaR antagonists that 
inhibit IgG-mediated effector functions. J Immunol, 2013. 191(1): p. 353-62. 
93. Stephens, D.S., B. Greenwood, and P. Brandtzaeg, Epidemic meningitis, 
meningococcaemia, and Neisseria meningitidis. Lancet, 2007. 369(9580): p. 2196-
210. 
94. Lewis, L.A. and S. Ram, Meningococcal disease and the complement system. 
Virulence, 2014. 5(1): p. 98-126. 
95. Uria, M.J., et al., A generic mechanism in Neisseria meningitidis for enhanced 
resistance against bactericidal antibodies. J Exp Med, 2008. 205(6): p. 1423-34. 
96. Kajander, T., et al., Dual interaction of factor H with C3d and glycosaminoglycans in 
host-nonhost discrimination by complement. Proc Natl Acad Sci U S A, 2011. 108(7): 
p. 2897-902. 
97. Lewis, L.A., et al., The meningococcal vaccine candidate neisserial surface protein A 
(NspA) binds to factor H and enhances meningococcal resistance to complement. 
PLoS Pathog, 2010. 6(7): p. e1001027. 
98. Madico, G., et al., The meningococcal vaccine candidate GNA1870 binds the 
complement regulatory protein factor H and enhances serum resistance. J Immunol, 
2006. 177(1): p. 501-10. 
99. Masignani, V., et al., Vaccination against Neisseria meningitidis using three variants 
of the lipoprotein GNA1870. J Exp Med, 2003. 197(6): p. 789-99. 
100. Fletcher, L.D., et al., Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. 
Infect Immun, 2004. 72(4): p. 2088-100. 
101. Serruto, D., et al., The new multicomponent vaccine against meningococcal 
serogroup B, 4CMenB: immunological, functional and structural characterization of 
the antigens. Vaccine, 2012. 30 Suppl 2: p. B87-97. 
Chapter ONE Bacterial immune evasion at the protein level: an introduction 
 
18 EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 
 
 
102. Pizza, M., et al., Identification of vaccine candidates against serogroup B 
meningococcus by whole-genome sequencing. Science, 2000. 287(5459): p. 1816-
20. 
103. Jarva, H., et al., Binding of the complement inhibitor C4bp to serogroup B Neisseria 
meningitidis. J Immunol, 2005. 174(10): p. 6299-307. 
104. Hubert, K., et al., Opc expression, LPS immunotype switch and pilin conversion 
contribute to serum resistance of unencapsulated meningococci. PLoS One, 2012. 
7(9): p. e45132. 
105. Griffiths, N.J., et al., Meningococcal surface fibril (Msf) binds to activated vitronectin 
and inhibits the terminal complement pathway to increase serum resistance. Mol 
Microbiol, 2011. 82(5): p. 1129-49. 
 
 
  
 
 
 
 
 
Chapter TWO 
 
 
High-throughput protein microarray screening 
revealed a novel Staphylococcus aureus C1q-
binding and complement inhibitor protein 
 
 
  
Chapter TWO FLIPr binds C1q and inhibits complement classical pathway 
 
20 EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 
 
 
Introduction  
Staphylococcus aureus is a gram-positive bacterium and opportunistic pathogen living as 
commensal in human skin and nasal cavities in 20% of humans [1, 2]. In some cases, S. 
aureus can infect humans causing a broad range of diseases, from superficial skin to 
invasive potentially life-threatening infections like endocarditis, pneumonia and sepsis. In 
addition, antibiotic treatment is often ineffective due to the development of many antibiotic 
resistant strains, the hypervirulent MDRS (Multi Drug Resistant Strains) which are spreading 
in many hospitals [3]. 
S. aureus, like many other pathogenic bacteria such as N. meningitides and group A and B 
Streptococcus (GAS and GBS), produce a wide variety of surface exposed and secreted 
proteins (usually described as “surfacome”) used for pathogenesis [4]. These proteins 
specifically bind host proteins causing bacterial adhesion, invasion and immune system 
deregulation and evasion. The S. aureus CWA (Cell Wall Anchored) protein family are 
surface exposed proteins covalently attached to peptidoglycan and are responsible for 
promoting adhesion to the extracellular matrix (ECM). Part of this class of proteins are the 
subclasses MSCRAMMs (Microbial Surface Component Recognizing Adhesive Matrix 
Molecules), that mediate the attachment to components of the host ECM, and NEAT (Near 
iron Transporter) proteins, involved in haem capture from haemoglobin. Examples of 
MSCRAMMs are the two fibrinogen-binding proteins ClfA (clumping factor A) and ClfB 
(clumping factor B) and other proteins involved in ECM binding such as SdrB, SdrC and 
SdrD, while IsdA and IsdB are typical NEAT proteins. Additional non-covalently associated 
surface proteins are represented by autolysin and adhesins which re-associate with the 
surface by ionic or hydrophobic interactions and have both enzymatic and adhesive functions 
[5]. In addition, S. aureus is remarkably able to control and subvert human innate immune 
response, especially the complement system, using a plethora of surface-exposed and 
secreted proteins [6]. Among the most studied there are the Staphylococcal Protein A (Spa) 
and Staphylococcal Binder of Immunoglobulins (Sbi) proteins, which bind IgG interfering with 
the complement classical pathway activation [7]. SCIN protein is instead able to bind the C3 
convertase (C3bBb) complex, responsible for C3 cleavage and complement amplification [8]. 
SSl7 binds to C5 and inhibits the conversion of C5 into C5a57 [9].  
The large number of interactions discovered so far, sometimes promiscuous and involving 
multiple components of the human defence apparatus, seems to suggest a very complex 
picture where additional interactions may take place at the host-pathogen interface. For this 
reason, a large-scale screening of human and staphylococcal proteins by protein microarray 
may represent an ideal tool for the identification of novel protein-protein interactions [10, 11].  
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In this study, protein microarray containing a large panel of S. aureus surface proteins was 
used to simultaneously investigate interactions with a library of human proteins potentially 
relevant during bacterial pathogenesis. Using this approach, several novel interactions 
between S. aureus and human proteins were identified. Among all, the interaction between 
FLIPr (FPRL1 inhibitory protein) and human C1q (complement component 1q) emerged as 
one of the most statistically relevant hit and it has been further characterized using 
biophysical and functional assays. 
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Experimental Procedures  
Selection, Cloning and Purification of SA Surface Proteins  
Genomic DNA coding for the mature portion of the Staphylococcus aureus proteins were 
cloned into the pET21b expression vector (Novagen) after PCR amplification using 
Escherichia coli BL21(DE3) (Novagen) as competent strain. Recombinant proteins (108 as 
single constructs and 10 as multiple constructs for a total of 159), obtained as C-terminal His 
or GST tag fusions, were expressed in HTMC (3% yeast extract, 40mM KH2PO4, 90mM 
K2HPO4, 2mM MgSO4, 1.5% glycerol, pH7.4) auto-inducing medium for 30h at 27°C and 
cell were then harvested at 6500xg for 1h. Bacterial lysis was obtained using B-PER buffer 
(Thermo Scientific) and the lysate was clarified by centrifugation at 30.000xg for 30min. The 
soluble fraction was loaded onto a His Multitrap HP 96-well plate system (GE Healthcare), 
washed with phosphate buffer (50 mM sodium phosphate, 300 mM NaCl, 20 mM imidazole 
pH 8.0) and the protein was finally eluted with the same buffer containing 250 mM imidazole 
as previously described in [12]. GST tagged proteins were purified using  a GST Multitrap HP 
96-well plate system (GE Healthcare), washed with phosphate buffer (50 mM Tris, 300 mM 
NaC pH 8.0). The proteins were eluted with the same buffer containing 10 mM reduced 
glutathione. Proteins purified in a tagless form were obtained as described by Klock et al. 
[13]. Briefly, the PCR product of the portion of the gene coding for the mature protein was 
cloned using the Polymerase Incomplete Primer Extension (PIPE) method into plasmid 
pSpeedET, which encodes an expression and purification tag followed by a tobacco etch 
virus protease site (MGSDKIHHHHHHENLYFQG) at the N terminus of the protein. E. coli 
strain HK100 was transformed with the plasmid coding for the protein and was grown in 
Luria-Bertani (LB) arabinose-containing broth until OD600= 0,4 - 0,6. Protein expression was 
achieved using IPTG (Isopropyl-β-D-thiogalactopyranosid) 1mM for 3h at 25°C. Cells were 
harvested at 6500xg for 1h and lysed in B-PER buffer (Thermo Scientific). Lysate was 
clarified by centrifugation at 30.000xg for 30min and the protein contained in the soluble 
fraction was purified using an automated AKTA x-PRESS system on a nickel affinity column, 
followed by a desalting step using 3 x 5 ml HiTrap Desalting columns equilibrated in 50 mm 
HEPES pH 8.0, 1 mm tris(2-carboxyethyl)phosphine (TCEP). Purified protein was digested 
overnight at 4°C with 1 mg of tobacco etch virus (TEV) protease/10 mg of eluted protein and 
was passed over a nickel affinity column collecting the flow-through. Purified proteins were 
stored at -20°C and analysed by SDS-PAGE and Matrix-Assisted Laser Desorption 
Ionization-Time Of Flight (MALDI-TOF) to assess their integrity, identity, and purity level 
(range of purity 60–90%). 
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Construction of the SA Surface Protein Microarray  
The SA protein microarray was generated by spotting purified recombinant proteins 
(0.5mg/ml in a final glycerol concentration of 40%) in 16 replicates on nitrocellulose coated 
slides (FAST slides; Whatman) using the ink-jet spotter Marathon (Arrayjet) resulting in spots 
of ~110 μm in diameter. Printing was performed in a cabinet with controlled humidity and 
temperature (55-60% and 12°C respectively). A standard curve made of eight concentrations 
(twofold dilution from 0.5 to 0.004 mg/ml) of an amino terminal FLAG-tagged protein (P7582 
Sigma), fluorescent BSA Cy3/Cy5 conjugated at 0,5 mg/ml and a standard curve of mouse 
IgGs  were used to obtain eigh replicates of a fluorescence standard curve to assess array 
coordinates and comparison of replicate experiments. 
Preliminary slide validation experiments, in which the slides were probed with mouse anti-
GST and anti-6xHis monoclonal antibodies followed by detection with a Cy5-conjugated anti-
mouse IgG secondary antibody, were performed to confirm the efficiency and reproducibility 
of the protein deposition on the chips. Nonspecific binding was minimized by preincubating 
arrays with a blocking solution containing NAP blocker (G-Bioscences) diluted 1:3 in PBS 
(Nap-PBS) for 1 hour. Human tagged proteins were diluted in Nap-PBS at final concentration 
of 10µg/ml and overlaid on the arrays (1 µg protein per slide) at RT for 1 h. After washing 
with 0.1% Tween 20 in PBS buffer (TPBS), arrays were incubated with mouse anti-FLAG 
(1:200– Sigma Aldrich) at RT for 1 h. Slides were washed again as before and interactions 
were detected by incubating with a Cy5 labeled anti-mouse antibody (Jackson 
Immunoresearch). Fluorescence images were obtained using Power scanner (Tecan Trading 
AG, Switzerland) and the 16-bit images were generated with PowerScanner software v1.2 at 
10 μm/pixel resolution and spot fluorescence intensities were determined using ImaGene 7.0 
software (Biodiscovery Inc.). Microarray data analysis was performed using in-house 
developed software. For each protein, the mean fluorescence intensity (MFI) of replicated 
spots was determined, after subtraction of the background value surrounding each spot. 
Signals were considered as positive when their MFI value was higher than 3,000, 
corresponding to the MFI of protein spots after detection with mouse anti-FLAG-Cy5 followed 
by an Cy5 labeled anti-mouse antibody, plus 3 standard deviation values. Negative control 
experiments were represented by slides incubated with anti-FLAG and anti-mouse antibodies 
only; the measured signals for each spot of the negative control slide was subtracted from 
those obtained for the same spot in the slides probed with human proteins. The average of 
the 16 spots replicates constitutes the mean fluorescent intensity (MFI) value taken in 
consideration for the validation experiments.  
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FLIPr expression and purification  
To obtain an amount of protein in a mg range, FLIPr (25-133) was expressed in BL21 E. coli 
(DE3) cells in HTMC autoinducing media (3% yeast extract, 40mM KH2PO4, 90mM K2HPO4, 
2mM MgSO4, 1.5% glycerol, pH7.4). Bacteria were grown for 30h at 27°C and cell were then 
harvested at 10000xg for 1h. Bacterial pellets were suspended in lysis buffer (50mM 
NaH2PO4 pH 8,2, 300mM NaCl supplemented with Roche EDTA-free protease inhibitors) 
lysate was clarified by centrifugation at 30.000xg for 30min. The histidine-tagged protein was 
purified using a nickel column (His Trap FF, 5 ml - GE Healthcare) following the 
manufacturer’s instructions. An additional step on Superdex 75 26/60 (Ge Healthcare) was 
performed to remove possible aggregates. Sample purity was checked by 4-12% SDS-PAGE 
and SE-UPLC.  
 
BioLayer Interferometry (BLI)-based OCTET analysis  
The interaction between C1q and FLIPr was characterized using an Octet QKe instrument 
(ForteBio, Pall Science). AR2G (amine reactive 2nd generation) tips were obtained from 
ForteBio and were used to covalently attach ligand protein using amine based chemistry. 
Immediately before analysis, AR2G tips were prewet in kinetic buffer (10mM HEPES, 300mM 
NaCl, 0,02% P-20 pH 7.4). During the entire kinetic assay the sample plate was kept shaking 
1000rpm. After 180 sec baseline, the biosensor tips were activated for 300 sec using a 
freshly mixed solution of 200 mM EDC in 50 mM NHS further diluted 1:20 in dH2O and the 
tips were then immersed in ligand solution for 600 sec loading (C1q 12.5 ug/ml in 10 mM 
NaH2PO4 pH 6.5, FLIPr 50ug/ml in 10 mM Na acetate pH 5). Excess reactive groups were 
blocked with 1 M ethanolamine pH 8.5 for 300 sec and a second 300 sec baseline in kinetic 
buffer was performed. A column of biosensors where no ligand protein was loaded, was 
activated and quenched to be used as parallel reference control in association with the 
analyte titration; a ligand-loaded biosensor was also used in association with buffer as 
baseline. 
Reference subtracted BLI response curves were used for the affinity constant determination. 
Inter-step correction and Y-alignment were used to minimize tip-dependent variability. Data 
were globally fit in a 1:1 model using the Data Analysis Software v7.1 (Forte Bio) 
 
Assessment of in vitro complement activity 
The assessment of in vitro complement activity was analysed using a complement screening 
kit (Wieslab COMP300). This enzyme based immunoassay was developed for the in vitro 
determination of complement dysfunctions in patients. The system relies on the specific 
FLIPr binds C1q and inhibits complement classical pathway Chapter TWO 
 
EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 25 
 
 
activation of the three distinct complement pathways (CP, MBL pathway and AP) through 
activators immobilized on the microtiter wells, using the deposition of the terminal MAC (C5-9) 
complex as readout. Buffers containing specific blockers to ensure the activation of the 
respective pathway were used to dilute the samples. For our purposes, serial concentrations 
(5uM, 1uM and 0,2uM) of FLIPr in HBS buffer (20mM HEPES, 150mM NaCl pH 7,3) were 
added to human serum previously diluted as suggested by supplier. Positive control was 
constituted by diluted serum and HBS buffer only, while negative control was constituted by 
heat inactivated serum. Additional control is represented by HBS buffer pre-incubated with 
serum.  The amount of complement activation correlates with the colour intensity measured 
as absorbance (OD) at 405 nm. The value for the positive control was defined as 100%; the 
value for negative control as 0%. All measured values were expressed as relative % of 
complement activation using the following formula: (sample value – negative control value) / 
(positive control value – negative control value) x 100. Student’s t test was used for 
comparison of paired means of two groups. P values of 0.05 were considered significant. 
 
Whole blood phagocytosis assay 
S. aureus survival in presence of FLIPr was assessed through whole blood phagocytosis 
assay. For such purpose an overnight culture of  S.aureus cells from USA 300 LAC strain in 
BHI, was diluted 1:40 and grown at 37°C with shaking 180 RPM to OD600=0.300. The 
5CFU) were 
added to 1 ml of fresh blood from healthy donors supplemented with anticoagulant lepirudin 
50 mg/L (20µl/ml of blood) and previously preincubated for 30 min at 37°C with different 
amount of FLIPr (0.4-3µM) or with PBS. A portion of this culture was plated on BHI-agar to 
determine the input CFU. The blood samples were  incubated with bacteria at 37°C for 2h 
with shaking 180 RPM. Aliquots were then incubated for 3 min on ice with a final 
concentration of 0.5% of saponin-PBS to lyse neutrophils. The number of viable bacteria was 
determined by serial tenfold dilutions in BHI and plating on BHI- agar plates. Colonies were 
counted after incubation of the plates at 37°C for 18 h. Control was the blood sample 
preincubated with PBS. 
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Results  
Microarray design and validation  
To shed light on the interactions between the Staphylococcus aureus surface proteome and 
the human innate immune system, a protein microarray screening was performed spotting 
159 S. aureus purified recombinant proteins (figure 2.1A and supplementary table 1) onto 
nitrocellulose coated slides. This microarray chip was used to be tested against a library of 
75 human recombinant purified proteins (figure 2.1B and supplementary table 2) resulting 
from the selection of a  larger library previously described [14]. All the S. aureus proteins 
printed on the arrays were selected using a combined bioinformatics and proteomic 
approach. The bacterial proteins were first selected by reverse vaccinology approach 
through bioinformatics analysis on S. aureus genome for the presence of a signal peptide, 
lipoprotein motifs, transmembrane regions and cell wall anchoring sequences and then 
integrated with surfome and secretome data resulting from the so called “protectome” [15]. 
The selected proteins all belong to the S. aureus strain NTCT 8325 genome except for some 
proteins coming from the Newman strain.  
 
Among all the predicted proteins, 118 unique proteins (108 as single constructs and 10 as 
multiple constructs for a total of 159) were chosen for spotting based on their purity level 
determined through SDS-PAGE and Peptide Mass Fingerprinting coupled to MALDI-TOF 
analysis (figure 2.2A). Among them, many are S. aureus toxins known to be relevant for 
bacterial pathogenesis such as the pore forming toxin HLA (Hemo-Lysin Alpha) [16], the 
fibrinogen-binding ClfA and ClfB [17], the extracellular adherence proteins Eap and Emp, and 
other virulence factors like EsxA, EsxB, FnBA and Ebps. Many of the spotted proteins were, 
A B 
Figure 2.1 Protein microarray design. (A) Classification of the Staphylococcus aureus proteins 
spotted on the chip based on their predicted localization and (B) of the 75 human proteins tested in 
the microarray screening on the base of their biological function. 
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on the other hand, of unknown function. Each protein was printed in 16 replicates all over the 
slide in a random fashion to prevent possible contamination between adjacent spots. 
Preliminary validation experiments in which the slides were probed with mouse anti-GST and 
anti-His6 tagged monoclonal antibodies followed by detection with a Cy5-conjugated anti-
mouse IgG secondary antibody confirmed that all S. aureus proteins were efficiently and 
reproducibly deposited and immobilized on the chips.  
 
 
A 
B 
C 
Figure 2.2 Protein microarray validation. (A) SDS-PAGE purity check of a set of S. aureus proteins 
purified with His Multitrap HP 96-well plate system. The purity was also determined by densitometry 
and MS analysis. (B) Fluorescence imaging detected using anti-FLAG and anti mouse antibodies of 
the spotted amino terminal FLAG-tagged protein used as control. Dilutions and replicates of the curve 
are shown. BSA Cy3/Cy5 was used for coordinates referencing. (C) Plot of the FLAG-tagged protein 
dilutions MFI values over their concentration. Curves best fit in a sigmoid curve. Standard deviation for 
each concentration is shown and refers to MFI of 30 different slides. 
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The interaction with human extracellular proteins was then studied by overlaying 75 human 
recombinant proteins selected from a larger library previously described [14]. Briefly, starting 
from previous large scale efforts and additional bioinformatic analysis, the gene coding for 
the ectodomain of 529 human proteins were cloned in plasmid for transient transfection, 
expressed with affinity tags (6xHis and FLAG) in HEK293 cells and purified in high-
throughput way. During the selection particular priority was given to those proteins known to 
be relevant during bacterial pathogenesis. In particular, adhesion factors, complement 
proteins, complement-related receptors and coagulation factors were used for this screening. 
The binding between two proteins was detected with anti-FLAG antibodies and subsequently 
with Cy5-conjugated anti-mouse IgG antibody. An amino terminal FLAG-tagged protein was 
also spotted on the array, in twofold dilutions, as detection control and for slide-to-slide 
normalization (figure 2.2B). The Mean Fluorescence Intensities (MFI) values of the FLAG-
tagged protein spots obtained after detection with anti-FLAG and Cy5-conjugated antibodies 
were fitted best by sigmoid curves (figure 2.2C), showing a signal dynamic range of about 2 
logs of fluorescence intensity values and a lower detection limit corresponding to ~0.03 ng. 
Mouse IgGs and PBS buffer were printed on the array as negative controls for spotting and 
detection while the Neisseria meningitidis fHbp (factor H binding protein) was printed as a 
positive control for interaction with human factor H that is part of the human library.  
Microarray screening and data analysis 
On the basis of the Mean Fluorescence Intensity (MFI) value of the controls, an MFI value 
greater than 3000 (equal to the mean signal of the controls spots after detection with anti-
Flag and anti-mouse alone, plus ten times standard deviation values) was determined as 
positive interaction. Three arbitrary MFI thresholds were also assigned for low (3000 to 
15000 MFI), medium (15000 to 30000 MFI) and high (30000 to saturation) reactivity between 
two proteins. Over a total of 11766 possible combinations, 11168 (94,92%) resulted below 
the background threshold and were thereby considered negative, while 598 (5,08%) resulted 
positive. Among these, 518 (4,40%) were established to be low, 61 (0,52%) medium and 19 
(0,16%) highly reactive (figure 2.3 upper left panel). If the data were analysed considering 
each human protein class (as defined in figure 2.1B and supplementary table 2) the global 
picture does not change (figure 2.3 and table 2.1). The adhesion factors and cell receptors 
classes are the most representative in the library being constituted by 35 proteins; over a 
total of 5565 combinations, 5287 were negative (95%), 241 (4,33%) low reactive, 29 medium 
(0,52%) and 8 high (0,14%). Within the proteins of the complement alternative pathway class, 
the negative combinations were 1506 (94,72%), the low reactive 73 (4,59%), the medium 8 
(0,50%) and the high 3 (0,19%) for a total of 1590 combinations. In the coagulation factors 
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and related receptors families, on a total of 1272 combinations, 1240 (97,48%) were negative, 
28 (2,20%) were low reactive, 3 medium (0,24%) and only 1 (0,08%) high. In the classical 
complement pathway class of proteins, interestingly, 6 combinations (0,34%) were highly 
reactive while 10 (0,57%) medium and 104 low (5.95%).  
 
 
 
adhesion 
factors/cell 
receptors/ 
others 
complement 
alternative 
pathway 
coagulation 
factors and 
related 
receptors 
complement 
classical 
pathway 
complement 
cascade 
complement 
lectin 
pathway 
complement 
related 
receptors 
total 
Proteins 35 10 8 11 6 2 2 74 
total n of 
combinations 
5565 1590 1272 1749 954 318 318 11766 
negative 
combinations 
5287 1506 1240 1629 923 279 304 11168 
combinations 
between 3K 
15K MFI 
241 73 28 104 28 33 11 518 
combinations 
between 15K 
30K MFI 
29 8 3 10 3 5 3 61 
combinations 
between 30K 
65K MFI 
8 3 1 6 0 1 0 19 
Table 2.1 Detailed microarray analysis divided based on human protein classes. Protein classes 
are shown in columns; colors used are the same as in figure 1B and supplementary table 2. 
 
The proteins from complement terminal pathway, did not show any highly reactive 
combination with the bacterial protein, while the medium and the low reactive were 
respectively 3 (2,94%) and 28 (0,31%). The Complement lectin pathway and the 
Figure 2.3 Screening results. Classification (differentiated for each human protein class) of the MFI 
values based on background and arbitrary thresholds. The 96% of the combinations between a S. 
aureus and human protein resulted below the background threshold (grey). The hits above 3000 MFI 
were classified in low (yellow - 4%), medium (orange - 0.36%) and highly reactive (red - 0.16%). 
Ficolin 2 was discarded from this analysis. 
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complement-related 
receptors classes were 
constituted by only 2 
proteins each with a total of 
318 possible combinations. 
Regarding the proteins from 
lectin pathway, only 1 
combination (0,31%) is 
highly reactive, while 5 
(1,57%) were medium and 
33 (10,38%) low. 
Considering the 
Complement related 
receptors class, none of the 
combination resulted highly 
reactive, while 3 (0,94%)  
were found to be medium 
and 11 (3,46%)  low.  
 
Within the 19 interactions 
showing high MFI signals 
two of the three spotted fHbp 
variants (variant 1 and 3), 
which constituted the 
positive control, were found 
when tested with human 
complement factor H present 
in the library.Among the 
tested human proteins, the 
Ficolin-2 showed high non-
specific signals with several 
bacterial proteins (figure 
2.4), and was thereby not 
considered in the analysis. 
In the same way, since the 
Figure 2.4 Schematic overview of the grid resulting from the 
screening. S. aureus proteins (lines) spotted on the chip were 
plotted against human proteins (columns) tested in overlay. 
Cells contain MFI value for each pair. The same colour code (grey - 
yellow - orange - red) is used for visual information and recognition 
of a putative interaction. Human complement factor H and ficolin 2 
and the bacterial fHbp v 1, 2 and 3, spA, FLIPr and Csa1D are 
highlighted 
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detection system relies on the use of antibodies and several human proteins were fused to 
an Fc-tag, the putative hits of the staphylococcal protein A (spA) were not considered for 
further validation knowing its ability to bind immunoglobulins.  
 
 
Figure 2.5 MFI signal distribution  of human proteins on spotted LytM and FLIPr proteins. 
Coloured columns identify the three MFI cut-off thresholds. Grey columns indicate proteins below the 
background threshold. (A) Plotting of MFIs of the 74 human proteins on the spotted LytM. Inset table 
shows MFI values, protein name and gene symbol of the 4 human proteins displaying fluorescence 
intensities above 30000 MFI. (B) Plotting of MFIs of the 74 human proteins on the spotted FLIPr. Inset 
table shows MFI values, protein name and gene symbol of the first 20 human proteins. C1qA, C1qB 
and C1qC subcomponents are highlighted in green.  
 
The rest of the highly reactive hits were shared between the staphylococcal Glycyl-glycine 
endopeptidase LytM (4 hits), the FPRL1 (formyl peptide receptor-like 1) inhibitory protein 
A 
B 
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(FLIPr) (6 hits), and the conserved staphylococcal antigen 1D (Csa1D) (1 hit). LytM (figure 
2.5A) showed high reactivity signals with the complement factor P (CFP - MFI 59922), the 
adiponectin protein (ADIPOQ - MFI 42215), the complement component 1q subcomponent 
like 4 (C1QL4 - MFI 32863) and the matrix remodelling associated protein 8 (MXRA8 - MFI 
31751). FLIPr, as well, showed several interesting putative interactors (figure 2.5B): the 
intercellular adhesion molecule 5 (ICAM5 - MFI 56363), the heat stable enterotoxin receptor 
(GUCY2C - MFI 52776), the complement component 1q subcomponent like 4 (C1QL4 - 
47822), the matrix remodelling associated protein 8 (MXRA8 - MFI 41675), the complement 
component 1q subcomponent B (C1QB - MFI 38610) and the bone sialoprotein 2 (IBSP  - 
MFI 37018). Interestingly FLIPr showed weaker but still reliable signals also with the 
complement component 1q subcomponent A (C1QA - MFI 15146), the complement 
component 1q subcomponent like 2 (C1QL2 - MFI 10381) and the complement component 
1q subcomponent C (C1QC - MFI 8302) among the others. Csa1D was instead highly 
reactive with ficolin 1 (FCN1 - MFI 34016). These and almost all the identified interactions 
are novel and would require further validation. Among them, the interaction between the 
staphylococcal protein FLIPr and the human C1q subcomponents seized our attention, since 
it involved key players of the offense/defense fighting taking place at the host-pathogen 
interface and it was never described before in literature. 
 
FLIPr binds to human C1q subcomponents and C1q complex 
To validate and characterize the binding between FLIPr and the C1q subcomponents, in vitro 
binding experiments were performed using BioLayer Interferometry (BLI). FLIPr protein was 
immobilized onto the BLI biosensor using amine reactive chemistry and C1qA, C1qB and 
C1qC subunits, previously used in the screening, were tested in titration curve as analytes. 
The three subcomponents showed low nanomolar affinity for FLIPr (3.2nM,  2.1nM and 
9.9nM respectively – Figure 2.6A-B-C). These data are in good agreement with MFI values 
obtained with protein array confirming a direct correlation between binding affinity and MFI 
values as also previously described [11, 18].  
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Figure 2.6 Binding of FLIPr to C1q subcomponents and C1q complex validated through 
BioLayer Interferometry. The amount of ligand associating with the analyte was measured in 
nanometres (nm). Blank subtracted sensograms of (A) C1qA (200-3.1nM), (B) C1qB (200-3.1nM) and 
(C) C1qC (200-12.5nM) subcomponents tested on covalently immobilized FLIPr. Association and 
dissociation curves were fitted in a 1:1 model. 
 
 
In biological conditions, however, the three C1qA, C1qB and C1qC subunits are super-
organized to constitute the C1q  complex, the triggering point of the classical complement 
pathway. For this reason, binding experiments between FLIPr and the human C1q complex 
affinity purified from human serum were performed. When immobilized, FLIPr showed 
picomolar affinity for the C1q complex (62 pM – Figure 2.7A). Conversely, when the C1q 
complex was immobilized, the measured affinity was in the high nanomolar range (679 nM – 
Figure 2.7B).  
  
C1qA (200 - 3.1nM) to FLIPr 
KD = 3.2 ± 0.02 nM 
C1qB (200 - 3.1nM) to FLIPr 
KD = 2.1 ± 0.02 nM 
C1qC (200 - 12.5nM) to FLIPr 
KD = 9.9 ± 0.13 nM 
A 
B 
C 
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Figure 2. 7 Binding of FLIPr to C1q complex (A) Blank subtracted sensograms of FLIPr (5-0.15 μM) 
on immobilized C1q and (B) of C1q (3-0.09 nM) on immobilized FLIPr 
 
A summary of the affinity constants and kinetic properties of the FLIPr-C1q complex is given 
in table3 
Ligand Analyte Kon (1/Ms) Koff (1/s) KD (M) 
FLIPr C1qA 2,84E+04 9,11E-05 3,21E-09 
FLIPr C1qB 4,10E+04 8,84E-05 2,16E-09 
FLIPr C1qC 1,22E+04 1,21E-04 9,97E-09 
FLIPr C1q complex 1,84E+06 1,14E-04 6,23E-11 
C1q FLIPr 2,93E+02 1,99E-04 6,80E-07 
 
FLIPr inhibits classical complement pathway in vitro 
In order to clarify whether the binding of FLIPr to C1q could influence complement classical 
pathway activation, a WiELISA (Wieslab) complement system screening kit was used. The 
system is based on ELISA plates pre-coated with specific activators of each complement 
pathway. Briefly, human serum was first diluted in specific buffers containing inhibitors for the 
pathways not under investigation, and then was applied to the WiELISA plate resulting in 
complement activation, monitored through the use of specific antibodies raised against a 
neo-epitope of the Membrane Attack Complex (MAC). Positive control was constituted by 
serum and negative control by heat inactivated serum. For our purposes, the complement 
classical pathway was investigated and the experimental design implied a preincubation of 
different amount of FLIPr with human serum. When pre-incubated with serum, FLIPr at 1µM  
C1q complex (3 - 0,09nM) to FLIPr 
KD = 62 ± 1 pM 
FLIPr  (5 - 0.015µM) to C1q complex 
KD = 679 ± 23 nM 
A 
B 
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significantly reduced to ~56% the complement classical pathway activation, while when at 
5µM the activation was reduced to ~26% (Figure 2.8A).  
FLIPr increases S. aureus survival in whole blood assay 
Since FLIPr was demonstrated to reduce the classical complement pathway activation, to 
improve the understanding in FLIPr contribution to bacterial pathogenesis, S. aureus survival 
in whole human blood (WHB) was monitored through CFU count in presence and absence of 
FLIPr. WHB pre-incubation with  FLIPr significantly increased S. aureus survival (Figure 
2.8B). When FLIPr was incubated at 1.4 µM an increase of 50% in the survival rate in 
comparison with control was observed, while when used at 2.8 µM, a 100% S. aureus 
survival was observed, in good agreement with Stemerding et al. 2013 [19]. 
 
   
Figure 2. 8 Functional characterization of the FLIPr C1q interaction. (A) Complement classical 
pathway inhibition by FLIPr in WiELISA assay. Relative % of complement activation is shown for each 
sample. Results are mean of three replicates. P values of 0.05 were considered significant. (B) FLIPr-
mediated dose dependent increase of S. aureus survival in whole blood assay. Relative survival was 
monitored through CFU count. 
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Discussion  
Staphylococcus aureus like many other opportunistic pathogens secretes and exposes on 
the surface a wide variety of proteins that specifically target the host immune system leading 
to bacterial adhesion, invasion and immune system evasion [20]. Several S. aureus 
molecules are known to interact with human immune system effectors. Plenty of examples 
are available: several proteins like the SCIN family were shown to act directly on complement 
cascade, directly blocking the innate immune response [8]; others like Cna (Collagen 
adhesin) and most of the MSCRAMM protein were shown to promote bacterial adhesion 
through collagen binding [21]; others, instead, acts to block phagocytosis and bacterial 
opsonisation by direct binding of receptors on phagocytes [22]. Even if a large number of 
human targets for staphylococcal proteins are already known and described, a lot of 
information on the surface interactome between S. aureus and human are still missing. 
Several studies utilized protein microarray as a key technique for the identification of novel 
host pathogen interaction at the protein level [11, 18]. Nevertheless, the limitation caused by 
the limited number of the human proteins available for the screening, led only to partial 
findings and results.  
In the protein array screening here presented, 118 unique S. aureus proteins, selected via a 
bioformatic approach, were efficiently cloned, expressed, purified and spotted on microarray 
slides. The chips were used to carry on, for the first time, an unbiased  systematic large-
scale screening using 75 human recombinant proteins obtained from a larger library [14]. 
The screening resulted in a total of 11766 combinations between pairs of human and S. 
aureus proteins. Among these, as expected, only a small proportion (<5%) gave a positive 
signal for interactions and, in particular, 457 (4%) putative interactions have been detected 
with a low signal, 42 (0,36%) with a medium and 19 (0,16%) with a highly reactive one, on 
the basis of their normalized MFI values. Within the 19 interactions showing high MFI signals 
two fHbp (fHbp variant 1 and variant 3, the positive controls) were present when incubated 
with complement factor H. This proves both the appropriate incubation conditions developed 
for the screening, the correct thresholds set for the analysis, and the integrity of the bacterial 
and human proteins used. With the use of such a large scale approach it was also possible 
to recognize and exclude from the analysis and validation those human proteins highly 
reactive with the great majority of bacterial proteins and vice versa. The human ficolin 2 and 
staphylococcal protein A, for example, were non-specifically reactive with several proteins 
and could be easily recognized and discarded from analysis and further validation. These 
two examples also constitutes a good proof of specificity for the other interaction found. 
Interestingly, the 17 hits (19 excluding the two fHbp) found in the array were shared between 
LytM, a staphylococcal autolysin previously shown to be an important regulator of S. aureus 
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cell cycle and cell wall turnover [23], Csa1D, member of the Conserved Staphylococcal 
Antigen family described as a promising vaccine antigen in Schluepen et al 2013 [24], and 
FLIPr, previously described as potent inhibitor of formyl-peptide receptors and FcγR 
antagonist [19, 25]. This last protein was found to interact, potentially strongly based on the 
detected signals, with six different human proteins: the intercellular adhesion molecule 5 
(ICAM5), the heat stable enterotoxin receptor (GUCY2C), the complement component 1q 
subcomponent like 4 (C1QL4), the matrix remodelling associated protein 8 (MXRA8), the 
complement component 1q subcomponent B (C1QB) and the bone sialoprotein 2 (IBSP). All 
the potential interactions found might be interesting for their relevance in the different steps 
of pathogenesis, but further work is currently needed to prove the functional and biological 
relevance of these interactions.  
On the other hand, a closer analysis of the human proteins reactive with FLIPr, to a lesser, 
but still significant extent, revealed additional potential interactors among which the 
complement component 1q subcomponent A (C1QA), the complement component 1q 
subcomponent like 2 (C1QL2) and the complement component 1q subcomponent C (C1QC - 
MFI 8302) caught our attention. The interaction between FLIPr and the components of the 
C1q complex was indeed never described before.  
Through the use of BioLayer Interferometry (BLI) the binding between FLIPr and the 
recombinant  C1q A, C1qB and C1qC components was validated. FLIPr was immobilized on 
the surface and the C1q components were tested as analyte. Using a 1:1 binding model, a 
nanomolar affinity was calculated for the C1qA and C1qC proteins while a  high picomolar 
affinity was measured for the C1qb component. Binding experiments were also performed 
with the C1q complex purified from human serum. In this case, when FLIPr was immobilized 
and the C1q used as analyte, the calculated affinity was in low picomolar range. However 
when the system was inverted and the C1q was immobilized, the calculated affinity was in 
the high nanomolar range. The reason of this discrepancy is still unclear and was not deeply 
investigated, but in our hypothesis, since the C1q complex possess possibly multiple binding 
sites for FLIPr, it is probably caused by an avidity effect of the C1q complex when FLIPr is 
immobilized, as also previously shown for other bacterial C1q-binding protein [26]. 
Together with the biophysical characterization of the interaction between FLIPr and the C1q 
complement component, functional studies were carried over as well to clarify the biological 
consequence of this protein complex. To this purpose WiELISA experiments and whole 
blood assays have been performed and confirmed the importance of FLIPr in bacterial 
pathogenesis. FLIPr was able to significantly reduce the complement classical pathway 
activation in vitro in WiELISA experiment. Despite this result, it is not yet clear if FLIPr 
directly prevent complement activation or whether it activates complement, leading to 
consumption of the complement proteins and thus resulting in a lower complement activation 
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in the assay, as also previously described for others bacterial proteins [27]. Moreover the 
whole blood assay, in which the addition of FLIPr resulted in dramatically higher S. aureus in 
vitro survival, confirmed the FLIPr importance and contribution in immune evasion. 
Since now FLIPr has always been described as potent inhibitor of the formyl-peptide and Fcγ 
receptors exposed on neutrophil surface. These data, which describes for the first time FLIPr 
as a C1q-binder and complement inhibitor protein, might explain why Stemerding et al. [19] 
did not see an inhibition of phagocitosis at high serum concentration. In their experiments 
fluorescently labelled S. aureus where opsonized with IgG, complement-inactivated human 
serum, or untreated human serum with intact complement activity and phagocytosis tests 
using human neutrophyls were performed. Staphylococci opsonized with IgG and 
complement-inactivated serum were fully protected from phagocytosis, but in the presence of 
complement, the inhibitory effects of FLIPr on phagocytosis was only observed at lower 
serum concentrations. A summary of the results obtained is shown in table 4.  
Work Assay Components FcγR  C1q Phagocytosis Survival Discussion 
Stemerding 
2013 
 
Phagocy
tosis 
IgG yes absent inhibited nd 
FLIPr inhibits 
phagocytosys 
through FcγR 
Phagocy
tosis 
complement 
inactivated 
serum 
yes 
present but 
inactive 
inhibited nd 
FLIPr inhibits 
phagocytosys 
through FcγR 
Phagocy
tosis 
active serum yes present 
inhibited only 
at low serum 
concentration 
nd 
FLIPr 
preferentially 
binds C1q 
instead of Fcg 
leading 
phagocytosis 
to occur 
this work 
whole 
blood 
assay 
blood yes present nd yes 
 
As the authors correctly argue, this effect might be explained with a complement receptor-
dependent phagocytosis. Combining the data present in literature and the functional data 
obtained in this work an "affinity driven model" was presented (figure 2.9). In this model 
when S. aureus faces low serum environment (e.g. interstitial space), FLIPr preferentially 
binds FcγR to inhibit neutrophil mediated phagocytosis. When S. aureus is instead exposed 
to high serum environment (e.g. blood) preferentially binds C1q. This can lead to both 
complement inhibition, resulting in FcγR mediated phagocytosis, or to complement activation, 
resulting as well in complement mediated phagocytosis. In this model S. aureus might 
selectively promote phagocytosis when it deals with unfavorable environment conditions 
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(complement pressure), preferring an intracellular lifestyle in neutrophils instead of 
bloodstream. This model can also represent a good proof of concept for the Trojan horse 
theorized by  Thwaites et al. [28] for which neutrophils represent a privileged site for S. 
aureus in the bloodstream, offers protection from most antibiotics and provides a mechanism 
by which the bacterium can travel to and infect distant sites.  
In summary it was demonstrated that protein microarray constitutes a powerful large scale 
tool for the screening and discovery of novel host-pathogen interactions. This approach lead 
to the identification of several novel protein-protein interactions between the human and the 
S. aureus extracellular proteomes and represents a proof-of-concept for future large scale 
screening on different pathogens.  
 
Figure 2.9 "Affinity driven" model. Schematic representation of the model for FLIPr selectivity for 
FcγR or C1q. Left panel shows a condition resembling interstitial space in which few C1q molecules 
are present. Some FLIPr molecules saturates the few C1q molecules and the rest can bind FcγR. This 
results in inhibition of both phagocytosis and killing. Right panel shows a situation similar to 
bloodstream, in which a lot of C1q molecules are present. FLIPr preferentially binds C1q molecules 
leaving FcγR free to operate. This results in phagocytosis as previously shown by Stemerding et al 
(2013), but does not result in killing (this work - whole blood assay). Staphylococci can indeed survive 
within neutrophils both preventing complement clearance and antibiotic treatment, and leading to 
bacterial spread in the body. 
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Supplementary table 1 
Common name, locus tag, gene product and lenght and localization of the S. aureus recombinant proteins printed on the microarray slides.  
Common 
name 
Locus tag gene product 
gene 
length 
localization 
 
gna1870 factor h binding protein 819 Outer membrane 
 
gna1870 factor h binding protein 819 Outer membrane 
 
gna1870 factor h binding protein 819 Outer membrane 
 
SAOUHSC_00051 1-phosphatidylinositol phosphodiesterase precursor, putative 328 Extracellular 
 
SAOUHSC_00052 putative lipoprotein 256 Unknown 
 
SAOUHSC_00052 putative lipoprotein 256 Unknown 
 
SAOUHSC_00053 putative lipoprotein 256 Unknown 
 
SAOUHSC_00054 staphylococcal tandem lipoprotein 256 Unknown 
 
SAOUHSC_00055 staphylococcal tandem lipoprotein 255 Unknown 
spa SAOUHSC_00069 protein A spA 516 Cell wall 
sasD SAOUHSC_00094 SasD protein SAOUHSC_00094 199 Cell wall 
 
SAOUHSC_00106 hypothetical protein , leader 514 Unknown 
 
SAOUHSC_00107 5' nucleotidase family protein 511 Extracellular 
isdI SAOUHSC_00130 heme-degrading monooxygenase IsdI 108 Unknown 
 
SAOUHSC_00170 extracellular solute-binding protein, RGD containing lipoprotein 591 Unknown 
 
SAOUHSC_00171 gamma-glutamyltranspeptidase, putative 668 Extracellular 
 
SAOUHSC_00172 hypothetical protein SAOUHSC_00172 257 Unknown 
 
SAOUHSC_00174 M23/M37 peptidase domain protein 192 Extracellular 
 
SAOUHSC_00176 bacterial extracellular solute-binding protein, putative 423 Unknown 
 
SAOUHSC_00186 lipoprotein, putative 322 Unknown 
coA SAOUHSC_00192 coagulase Coa 636 Extracellular 
 
SAOUHSC_00201 putative extracellular solute-binding protein 470 Cell wall 
 
SAOUHSC_00248 peptidoglycan hydrolase, putative 316 Extracellular 
 
SAOUHSC_00256 secretory antigen SsaA-like protein 297 Unknown 
esxA SAOUHSC_00257 hypothetical protein SAOUHSC_00257 97 Unknown 
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esxB SAOUHSC_00265 hypothetical protein SAOUHSC_00265 104 Cytoplasmic 
 
SAOUHSC_00279 putative lipoprotein 124 Cytoplasmic 
 
SAOUHSC_00300 lipase precursor 690 Extracellular 
 
SAOUHSC_00354 staphylococcal enterotoxix, putative 203 Unknown 
 
SAOUHSC_00356 putative lipoprotein 190 Unknown 
 
SAOUHSC_00362 putative lipoprotein 208 Unknown 
 
SAOUHSC_00365 alkyl hydroperoxide reductase 189 Cytoplasmic 
 
SAOUHSC_00383 superantigen-like protein 226 Unknown 
 
SAOUHSC_00384 superantigen-like protein 231 Unknown 
 
SAOUHSC_00386 superantigen-like protein 356 Extracellular 
 
SAOUHSC_00389 superantigen-like protein 308 Extracellular 
 
SAOUHSC_00390 superantigen-like protein 5 234 Extracellular 
 
SAOUHSC_00391 superantigen-like protein 231 Extracellular 
 
SAOUHSC_00392 superantigen-like protein 7 231 Extracellular 
 
SAOUHSC_00393 superantigen-like protein 232 Extracellular 
 
SAOUHSC_00394 superantigen-like protein 232 Extracellular 
 
SAOUHSC_00395 superantigen-like protein 227 Extracellular 
 
SAOUHSC_00399 superantigen-like protein 225 Extracellular 
 
SAOUHSC_00400 putative surface protein 502 Unknown 
 
SAOUHSC_00404 putative lipoprotein 261 Unknown 
 
SAOUHSC_00427 autolysin precursor, putative 334 Extracellular 
sdrC SAOUHSC_00544 sdrC protein, putative 995 Cell wall 
sdrD SAOUHSC_00545 sdrD protein, putative 1349 Cell wall 
 
SAOUHSC_00634 ABC transporter, substrate-binding protein, putative \lipoprotein 312 Unknown 
 
SAOUHSC_00661 probable lipase 347 Unknown 
 
SAOUHSC_00671 secretory antigen SsaA-like protein 265 Extracellular 
 
SAOUHSC_00685 putative lipoprotein 131 Unknown 
 
SAOUHSC_00717 lipoprotein 146 Unknown 
 
SAOUHSC_00728 Predicted membrane-associated, metal-dependent hydrolase 646 
Cytoplasmic/Membran
e 
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SAOUHSC_00749 Siderophore binding protein FatB 342 Unknown 
 
SAOUHSC_00754 ferrichrome  binding protein 292 Unknown 
 
SAOUHSC_00773 immunogenic secreted precursor-like protein (truncated) 279 Unknown 
 
SAOUHSC_00808 putative lipoprotein 242 Unknown 
 
SAOUHSC_00814 
truncated secreted von Willebrand factor-binding protein (coagulase) VWbp, 
putative 
450 Extracellular 
Emp SAOUHSC_00816 extracellular matrix and plasma binding protein, putative 340 Unknown 
 
SAOUHSC_00817 hypothetical protein SAOUHSC_00817 \ von willebrand truncated 156 Unknown 
 
SAOUHSC_00860 5-nucleotidase family protein 439 Extracellular 
 
SAOUHSC_00872 extramembranal protein 391 Cytoplasmic 
 
SAOUHSC_00987 cysteine protease precursor, putative 393 Extracellular 
 
SAOUHSC_00988 glutamyl endopeptidase precursor, putative 336 Extracellular 
 
SAOUHSC_00998 fmt protein, putative 397 Extracellular 
 
SAOUHSC_01005 chitinase 105 Unknown 
 
SAOUHSC_01039 putative lipoprotein 208 Unknown 
isdB SAOUHSC_01079 neurofilament protein isdB 645 Cell wall 
isdA SAOUHSC_01081 IsdA protein 350 Cell wall 
IsdC SAOUHSC_01082 hypothetical protein SAOUHSC_01082 isdC 227 Cellwall 
 
SAOUHSC_01084 hypothetical iron-regulated protein, leader isdD 358 Unknown 
 
SAOUHSC_01085 iron ABC transporter, iron -binding protein IsdE 282 Cytoplasmic 
 
SAOUHSC_01088 NPQTN specific sortase B 244 Unknown 
isdG SAOUHSC_01089 heme-degrading monooxygenase IsdG 107 Cytoplasmic 
 
SAOUHSC_01110 fibrinogen-binding protein-related 109 Unknown 
FLIPr SAOUHSC_01112 formyl peptide receptor-like 1 inhibitory protein 133 Unknown 
efb SAOUHSC_01114 fibrinogen-binding protein 165 Extracellular 
 
SAOUHSC_01115 scin paralogue 116 Unknown 
hla SAOUHSC_01121 alpha-hemolysin precursor 319 Extracellular 
 
SAOUHSC_01124 superantigen-like protein 238 Extracellular 
 
SAOUHSC_01125 superantigen-like protein 241 Extracellular 
 
SAOUHSC_01150 cell division protein FtsZ 390 Cytoplasmic 
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SAOUHSC_01180 putative lipoprotein 317 Unknown 
 
SAOUHSC_01256 insulysin, peptidase family M16 428 Unknown 
nuc SAOUHSC_01316 thermonuclease precursor 177 Extracellular 
 
SAOUHSC_01317 hypothetical protein leader? 284 Unknown 
ebpS SAOUHSC_01501 elastin binding protein EbpS 486 Cell wall 
 
SAOUHSC_01508 putative lipoprotein 304 Unknown 
 
SAOUHSC_01627 putative lipoprotein 193 Unknown 
 
SAOUHSC_01920 putative lipoprotein 208 Unknown 
 
SAOUHSC_01941 serine protease SplB 240 Extracellular 
 
SAOUHSC_01949 intracellular serine protease, putative 457 Extracellular 
 
SAOUHSC_01972 protein export protein PrsA, putative 320 Unknown 
 
SAOUHSC_02127 staphopain thiol proteinase 388 Extracellular 
 
SAOUHSC_02147 hypothetical protein, putative leader 280 Unknown 
eap SAOUHSC_02161 MHC class II analog protein 584 Unknown 
 
SAOUHSC_02167 hypothetical protein SAOUHSC_02167 116 Unknown 
 
SAOUHSC_02169 chemotaxis-inhibiting protein CHIPS 149 Unknown 
 
SAOUHSC_02240 truncated beta-hemolysin 274 Extracellular 
lukF SAOUHSC_02241 Leukocidin/Hemolysin toxin family LukF 338 Extracellular 
 
SAOUHSC_02246 ferric hydroxamate receptor 1 303 Unknown 
 
SAOUHSC_02257 srdH family protein 419 Cell wall 
 
SAOUHSC_02333 Probable transglycosylase isaA precursor 231 Extracellular 
 
SAOUHSC_02463 hyaluronate lyase 807 Extracellular 
 
SAOUHSC_02554 ferrichrome-binding protein TroA-like -FhuD2? 302 Unknown 
 
SAOUHSC_02576 secretory antigen precursor SsaA, putative 166 Unknown 
 
SAOUHSC_02706 immunoglobulin G-binding protein Sbi, putative 436 Unknown 
 
SAOUHSC_02708 gamma-hemolysin h-gamma-ii subunit, putative 309 Extracellular 
 
SAOUHSC_02767 peptide ABC transporter, peptide-binding protein, putative 532 Cell wall 
 
SAOUHSC_02783 hypothetical protein, putative leader 264 Unknown 
FnBA SAOUHSC_02803 fibronectin-binding protein A precursor FnBPA 990 Cell wall 
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SAOUHSC_02887 immunodominant antigen A, putative 233 Extracellular 
clfB SAOUHSC_02963 clumping factor B, putative 877 Cell wall 
 
SAOUHSC_02979 N-acetylmuramoyl-L-alanine amidase 619 Extracellular 
sasF SAOUHSC_02982 sasF protein 635 Cell wall 
 
SAOUHSC_03006 lipase 680 Extracellular 
NW_1 
   
Unknown 
NW_2 
   
Unknown 
NW_sdrE NWMN_0525 Serine-aspartate repeat-containing protein E 3498 Unknown 
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Supplementary table 2 
Name, function and UniProt description of the 75 human recombinant proteins used in the microarray screening. The proteins are 
divided by colours for function, based on the biological process they are involved in. Colours are the same reported in figure 1A. N.D indicates 
that no uniprot description was available. 
Function Name Gene name Description 
adhesion / 
cell 
receptors / 
various 
Adiponectin  ADIPOQ 
Important adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic and anti-
inflammatory activities. Stimulates AMPK phosphorylation and activation in the liver and the skeletal muscle, enhancing glucose utilization and 
fatty-acid combustion. Antagonizes TNF-alpha by negatively regulating its expression in various tissues such as liver and macrophages, and also 
by counteracting its effects. Inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway. May play a role in cell growth, 
angiogenesis and tissue remodeling by binding and sequestering various growth factors with distinct binding affinities, depending on the type of 
complex, LMW, MMW or HMW 
Anthrax toxin 
receptor 1 
Antxr1 
Plays a role in cell attachment and migration. Interacts with extracellular matrix proteins and with the actin cytoskeleton. Mediates adhesion of 
cells to type 1 collagen and gelatin, reorganization of the actin cytoskeleton and promotes cell spreading. Plays a role in the angiogenic response 
of cultured umbilical vein endothelial cells. 
Anthrax toxin 
receptor 2  
Antxr2  n.d. 
Basal cell 
adhesion 
molecule  
BCAM Laminin alpha-5 receptor. May mediate intracellular signaling 
Bone sialoprotein 
2  
IBSP 
Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction. Promotes 
Arg-Gly-Asp-dependent cell attachment. 
Carcinoembryonic 
antigen related 
cell adhesion 
molecule 1  
CEACAM1  n.d. 
Cartilage 
oligomeric matrix 
protein 
COMP 
May play a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and 
fibronectin. Can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin 
receptors. Could play a role in the pathogenesis of osteoarthritis. Potent suppressor of apoptosis in both primary chondrocytes and transformed 
cells. Suppresses apoptosis by blocking the activation of caspase-3 and by inducing the IAP family of survival proteins (BIRC3, BIRC2, BIRC5 
and XIAP). Essential for maintaining a vascular smooth muscle cells (VSMCs) contractile/differentiated phenotype under physiological and 
pathological stimuli. Maintains this phenotype of VSMCs by interacting with ITGA7 (By similarity). 
Cell adhesion 
molecule 1  
Cadm1  n.d. 
Cell adhesion 
molecule 3  
CADM3 
Involved in the cell-cell adhesion. Has both calcium-independent homophilic cell-cell adhesion activity and calcium-independent heterophilic cell-
cell adhesion activity with IGSF4, PVRL1 and PVRL3. Interaction with EPB41L1 may regulate structure or function of cell-cell junctions (By 
similarity). 
Cell surface 
glycoprotein 
MUC18 
MCAM 
Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow 
melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion 
molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and 
PTK2/FAK1, and a transient increase in the intracellular calcium concentration. 
Endothelial cell 
selective 
adhesion 
molecule  
ESAM Can mediate aggregation most likely through a homophilic molecular interaction 
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Epithelial cell 
adhesion 
molecule  
EPCAM 
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the 
mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells 
proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E 
Epithelial cell 
adhesion 
molecule 
precursor  
EPCAMP  n.d. 
Extracellular 
matrix protein 1  
ECM1 
Involved in endochondral bone formation as negative regulator of bone mineralization. Stimulates the proliferation of endothelial cells and 
promotes angiogenesis. Inhibits MMP9 proteolytic activity 
Extracellular 
matrix protein 2  
ECM2 Promotes matrix assembly and cell adhesiveness 
Fibroleukin FGL2 May play a role in physiologic lymphocyte functions at mucosal sites 
Glucagon 
preproprotein  
   n.d. 
Heat stable 
enterotoxin 
receptor  
GUCY2C 
Receptor for the E.coli heat-stable enterotoxin (E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing 
GC-C). Also activated by the endogenous peptides guanylin and uroguanylin. 
Integrin alpha L ITGAL 
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-
endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. 
Integrin alpha M  ITGAM 
Integrin alpha-M/beta-2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the 
uptake of complement-coated particles. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It 
probably recognizes the R-G-D peptide in C3b. Integrin alpha-M/beta-2 is also a receptor for fibrinogen, factor X and ICAM1. It recognizes P1 and 
P2 peptides of fibrinogen gamma chain. 
Integrin beta 2 ITGB2 
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins alpha-M/beta-2 and alpha-X/beta-2 are receptors for the 
iC3b fragment of the third complement component and for fibrinogen. Integrin alpha-X/beta-2 recognizes the sequence G-P-R in fibrinogen alpha-
chain. Integrin alpha-M/beta-2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin alpha-M/beta-2 is also a receptor for factor X. 
Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1. Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated 
activation 
Intercellular 
adhesion 
molecule 1  
ICAM1 
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 
engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation. In case of rhinovirus infection 
acts as a cellular receptor for the virus 
Intercellular 
adhesion 
molecule 2  
ICAM2 
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). ICAM2 may play a role in lymphocyte recirculation 
by blocking LFA-1-dependent cell adhesion. It mediates adhesive interactions important for antigen-specific immune response, NK-cell mediated 
clearance, lymphocyte recirculation, and other cellular interactions important for immune response and surveillance. 
Intercellular 
adhesion 
molecule 3  
ICAM3 ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). ICAM3 is also a ligand for integrin alpha-D/beta-2. 
Intercellular 
adhesion 
molecule 4  
ICAM4 
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). ICAM4 is also a ligand for alpha-4/beta-1 and alpha-
V integrins. 
Intercellular 
adhesion 
molecule 5  
ICAM5 ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). 
Matrix Gla protein  MGP  Associates with the organic matrix of bone and cartilage. Thought to act as an inhibitor of bone formation. 
Matrix remodeling 
associated 
Mxra8 May play a role in the maturation and maintenance of blood-brain barrier. 
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protein 8  
Mucosal 
addressin cell 
adhesion 
molecule 1  
Madcam1  n.d. 
Neural cell 
adhesion 
molecule 1  
NCAM1 This protein is a cell adhesion molecule involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc 
Neural cell 
adhesion 
molecule 2  
NCAM2 May play important roles in selective fasciculation and zone-to-zone projection of the primary olfactory axons. 
Single 
immunoglob 
tollinterleu 1 
receptor (TIR)  
SIGIRR 
Acts as a negative regulator of the Toll-like and IL-1R receptor signaling pathways. Attenuates the recruitment of receptor-proximal signaling 
components to the TLR4 receptor, probably through an TIR-TIR domain interaction with TLR4. Through its extracellular domain interferes with the 
heterodimerization of Il1R1 and IL1RAP 
Spondin 1  SPON1 
Cell adhesion protein that promotes the attachment of spinal cord and sensory neuron cells and the outgrowth of neurites in vitro. May contribute 
to the growth and guidance of axons in both the spinal cord and the PNS (By similarity). Major factor for vascular smooth muscle cell. 
Toll like receptor 
2  
TLR2 
Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with 
TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides. Acts via MYD88 and TRAF6, leading to NF-kappa-
B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins. Recognizes 
mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and 
B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6. 
Vitronectin  VTN 
Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is 
recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging 
effect of the terminal cytolytic complement pathway. 
complement 
alternative 
pathway 
CD46 molecule 
complement 
regulatory protein  
CD46 
Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving 
C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a 
costimulatory factor for T-cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune 
responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity. A number of viral and bacterial pathogens seem to 
exploit this property and directly induce an immunosuppressive phenotype in T-cells by binding to CD46 
Complement 
factor B  
CFB  
Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine 
protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and 
differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of 
erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes. 
Complement 
factor D (adipsin)  
CFD 
Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of 
the alternate pathway. Its function is homologous to that of C1s in the classical pathway. 
Complement 
Factor H  
CFH 
Factor H functions as a cofactor in the inactivation of C3b by factor I and also increases the rate of dissociation of the C3bBb complex (C3 
convertase) and the (C3b)NBB complex (C5 convertase) in the alternative complement pathway. 
Complement 
factor H related 1  
CFHR1 
Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the 
physiological complement inhibitor CFH. Can associate with lipoproteins and may play a role in lipid metabolism 
Complement 
factor H related 2  
CFHR2 
Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the 
physiological complement inhibitor CFH. Can associate with lipoproteins and may play a role in lipid metabolism 
Complement 
factor H related 4  
CFHR4 Involved in complement regulation. Can associate with lipoproteins and may play a role in lipid metabolism. 
Complement 
factor H related 5  
CFHR5 
Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the 
physiological complement inhibitor CFH 
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Complement 
factor I  
CFI  Responsible for cleaving the alpha-chains of C4b and C3b in the presence of the cofactors C4-binding protein and factor H respectively 
Complement 
factor properdin  
CFP A positive regulator of the alternate pathway of complement. It binds to and stabilizes the C3- and C5-convertase enzyme complexes 
coagulation 
factors and 
related 
receptors 
Fibrinogen beta 
chain  
FGB 
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to 
form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions 
during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be 
essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However subsequent studies have shown that it is not 
absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets. Maternal fibrinogen is essential for 
successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate 
the antibacterial immune response via both innate and T-cell mediated pathways. 
Fibrinogen 
gamma chain  
FGG 
Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in 
hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion 
and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using 
anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances 
expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin 
deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune 
response via both innate and T-cell mediated pathways 
Fibrinogen like 
protein 1  
FGL1 Has hepatocyte mitogenic activity. 
Platelet endot cell 
adhesion 
molecule 
precursor 
PECAM1 
Induces susceptibility to atherosclerosis (By similarity). Cell adhesion molecule which is required for leukocyte transendothelial migration (TEM) 
under most inflammatory conditions. Tyr-690 plays a critical role in TEM and is required for efficient trafficking of PECAM1 to and from the lateral 
border recycling compartment (LBRC) and is also essential for the LBRC membrane to be targeted around migrating leukocytes. Prevents 
phagocyte ingestion of closely apposed viable cells by transmitting 'detachment' signals, and changes function on apoptosis, promoting tethering 
of dying cells to phagocytes (the encounter of a viable cell with a phagocyte via the homophilic interaction of PECAM1 on both cell surfaces leads 
to the viable cell's active repulsion from the phagocyte. During apoptosis, the inside-out signaling of PECAM1 is somehow disabled so that the 
apoptotic cell does not actively reject the phagocyte anymore. The lack of this repulsion signal together with the interaction of the eat-me signals 
and their respective receptors causes the attachment of the apoptotic cell to the phagocyte, thus triggering the process of engulfment). Isoform 
Delta15 is unable to protect against apoptosis. Modulates BDKRB2 activation. Regulates bradykinin- and hyperosmotic shock-induced ERK1/2 
activation in human umbilical cord vein cells (HUVEC). 
Platelet 
endothelial cell 
adhesion 
molecule  
PECAM1 
Von W factor C 
domain protein 
like 2   
VWA2  n.d. 
Von Will factor A 
domain 
containing protein 
2  
VWCE May be a regulatory element in the beta-catenin signaling pathway and a target for chemoprevention of hapatocellular carcinoma 
Von Willebrand 
factor C and EGF 
domain 
containing protein 
VWC2L May play a role in neurogenesis. May play a role in bone differentiation and matrix mineralization 
complement 
classical 
pathway 
Complement 
component 1 q 
subcomponent A 
chain 
C1QA 
C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of 
C1q interact with the Ca2+-dependent C1r2C1s2 proenzyme complex, and efficient activation of C1 takes place on interaction of the globular 
heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes 
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Complement 
component 1 q 
subcomponent B 
chain 
C1QB 
Complement 
component 1 q 
subcomponent C 
chain 
C1QC 
Complement 
component 1 q 
subcomponent 
like 1 
C1QL1 
May regulate the number of excitatory synapses that are formed on hippocampus neurons. Has no effect on inhibitory synapses (By similarity). 
Complement 
component 1 q 
subcomponent 
like 2 
C1QL2 
Complement 
component 1 q 
subcomponent 
like 4 
C1QL4 
Complement 
component 1 r 
subcomponent  
C1R 
C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement 
system. 
Complement 
component 1 r 
subcomponent 
like  
C1RL Mediates the proteolytic cleavage of HP/haptoglobin in the endoplasmic reticulum 
Complement 
component 1 s 
subcomponent  
C1S 
C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement 
system. C1r activates C1s so that it can, in turn, activate C2 and C4. 
Complement 
component 2 
(within H 2S) 
C2 
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and 
alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune 
aggregates. Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic 
inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular 
permeability and causes histamine release from mast cells and basophilic leukocytes. C3-beta-c: Acts as a chemoattractant for neutrophils in 
chronic inflammation 
Complement 
component 4 
binding protein, 
beta 
C4BPB 
Controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the 
complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment 
C2a. It also interacts with anticoagulant protein S and with serum amyloid P component. The beta chain binds protein S. 
complement 
terminal 
pathway 
Complement 
component 6  
C6 
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the 
plasma membrane of target cells. 
Complement 
component 7  
C7 
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the 
plasma membrane of target cells. C7 serves as a membrane anchor 
Complement 
component 8 
alpha polypeptide  
C8A 
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the 
plasma membrane of target cells. C8A inserts into the target membrane, but does not form pores by itself 
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Complement 
component 8 beta 
polypeptide  
C8B 
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the 
plasma membrane of target cells 
Complement 
component 8 
gamma 
polypeptide  
C8G 
C8 is a constituent of the membrane attack complex. C8 binds to the C5B-7 complex, forming the C5B-8 complex. C5-B8 binds C9 and acts as a 
catalyst in the polymerization of C9. The gamma subunit seems to be able to bind retinol. 
Complement 
factor 9  
C9 
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the 
plasma membrane of target cells. C9 is the pore-forming subunit of the MAC. 
complement 
lectin 
pathway 
Ficolin 1   FCN1 
Extracellular lectin functioning as a pattern-recognition receptor in innate immunity. Binds the sugar moieties of pathogen-associated molecular 
patterns (PAMPs) displayed on microbes and activates the lectin pathway of the complement system. May also activate monocytes through a G 
protein-coupled receptor, FFAR2, inducing the secretion of interleukin-8/IL-8 (PubMed:21037097). Binds preferentially to 9-O-acetylated 2-6-
linked sialic acid derivatives and to various glycans containing sialic acid engaged in a 2-3 linkage 
Ficolin 2 FCN2 
May function in innate immunity through activation of the lectin complement pathway. Calcium-dependent and GlcNAc-binding lectin. Enhances 
phagocytosis of S.typhimurium by neutrophils, suggesting an opsonic effect via the collagen region 
Ficolin 3   FCN3 
May function in innate immunity through activation of the lectin complement pathway. Calcium-dependent and GlcNAc-binding lectin. Has affinity 
with GalNAc, GlcNAc, D-fucose, as mono/oligosaccharide and lipopolysaccharides from S.typhimurium and S.minnesota 
complement 
related 
receptors 
Compl comp (3d 
Epstein Barr 
virus) receptor 2  
CR1L  n.d. 
Complement 
component 
(3b4b) receptor 1 
like 
CR2 Receptor for complement C3Dd, for the Epstein-Barr virus on human B-cells and T-cells and for HNRPU. Participates in B lymphocytes activation 
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Introduction 
Neisseria meningitidis is a gram negative encapsulated bacterium and commensal of human 
nasopharynx. For still not completely understood reasons, it may become an aggressive 
pathogen leading to fulminant sepsis and meningitides. Invasive meningococcal disease 
(IMD) is calculated to cause 5–15% mortality; in addition, overwhelming events affecting 
quality of life such as amputations and neurodevelopmental disabilities are shown in 11–19% 
of IMD survivors [1]. Twelve serogroups were described on the base of their capsular 
polysaccaride, but the majority of invasive meningococcal infections are caused by 
serogroups A, B, C, X, W-135 and Y. The annual number of disease caused worldwide is 
calculated to be at least 1.2 million, with 135,000 deaths related to IMD [2]. Since the early 
1990s, effective vaccines against N. meningitidis serogroups A, C, W, and Y based on mono- 
or polyvalent-conjugated polysaccharide were available [3]. However, the structural similarity 
of the serogroup B meningococcus (MenB) capsular polysaccaride with the neuraminic acid 
present on the surface of human fetal neural tissues [4], prevented the development of an 
efficient capsular polysaccharide-based vaccine against MenB, responsible for the majority 
of endemic and epidemic meningococcal disease in developed countries [5, 6]. The effort to 
develop an effective vaccine against MenB resulted in the recent release of the Bexsero 
vaccine licensed by Novartis Vaccines and Diagnostics. Bexsero is a four component protein 
based vaccine (4CMenB) composed of three surface-exposed meningococcal proteins 
identified by the reverse vaccinology approach plus outer membrane vesicles (OMV) from 
the New Zealand epidemic clone [7, 8]. The three protein antigens are factor H-binding 
protein (fHbp), neisserial heparin-binding antigen (NHBA) and neisserial adhesin A (NadA).  
NadA is a trimeric coiled-coil outer membrane protein whose gene is present in three out of 
four known hypervirulent lineages of serogroup B strains [9]. NadA is usually classified in the 
trimeric autotransporter adhesion (TAA) family, a class of outer membrane adhesin present 
in Gram-negative bacteria. Nevertheless, the recently solved structure showed features of a 
novel trimeric autotransporter adhesin that has no close homologs among other TAAs 
proteins present in the Protein Data Bank (PDB) [10]. The protein is constituted by a trimeric 
coiled-coil structure which includes both the apical N-terminal region and the main stalk, with 
a peculiar sequence insertion which gives rise to wing-like structures without altering the 
coiled-coil geometry.  
Several studies, carried out on different cell types including epithelial cells, monocytes, 
macrophages, and monocyte-derived dendritic cells, showed NadA’s importance in bacterial 
adhesion. NadA have been shown to be involved in bacterial uptake in epithelial cells. E coli 
bacteria expressing NadA were indeed shown to be internalized in Chang cells in a NadA-
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dependent fashion. In addition a deletion of the N-terminal globular domain of recombinant 
NadA abrogated the adhesive phenotype [11]. Additional studies revealed the regions 
between aminoacids 94 to 110 and 109 to 121 on NadA head as the one involved in  NadA-
mediated cell-bacterium adhesion [12]. Further studies have shown that recombinant NadA 
binds to hsp90 in vitro and on the surface of monocytes [13]. In the proposed model, NadA 
binds to an unknown receptor, encounters hsp90 probably by lateral diffusion and then it is 
recruited into a complex also comprising hsp70 and TLR4. This complex is inhibited by 
polymixin B, which interferes whith NadA-hsp90 binding but not with NadA cell binding. The 
complex is also necessary for full monocyte stimulation and may be important to modulate or 
enhance the vaccine immune response. Furthermore NadA has been shown to interact with 
β-integrins on epithelial-like GE-11 and fibroblast-like 2-4-8 cells using flow cytometry. The 
direct binding data have been corroborated by blocking experiments with anti-human integrin 
β1 monoclonal antibodies which have been described to compete with NadA for β-integrin 
binding [14]. Based on these studies, NadA appears to be a key determinant of 
meningococcal interactions with the human host at different stages of meningococcal 
infection. However, specific molecular interactions taking place at the host-pathogen 
interface are still not completely understood. In order to identify novel human receptors for 
NadA, an un-biased systematic large scale protein microarray-based approach for the 
identification of novel interactions was applied. In particular, NadA variant 3 (NadA3) was 
screened for interactions against ~2700 recombinant proteins representing the “human 
extracellular proteome” [15] and label-free technologies and FACS analysis were used for hit 
validation. 
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Materials and methods 
Protein microarray construction and processing   
The NOV-GNF protein microarrays were generated by using 2354 human recombinant 
proteins from the GNF library, which were produced as described in Gonzalez et al. (2009). 
Each protein of the library was spotted in duplicates in 24 blocks per array onto ultra-thin 
nitrocellulose coated glass slides (PATH slides; Grace Bio Labs) using a contact printer 
(MicroGrid II; Digilab). Printing was performed at room temperature and ambient relative 
humidity. Proteins were diluted ½ in arraying buffer (100 mM NaCl, 0.05% TritonX and 5% 
Glycerol in PBS) and printed between 10 amol to 75 fmol per 150 µm diameter spot. A 
Chrompure human IgG (Jackson IR 009-000-003) was printed at 0.4 fmol per spot several 
times on each single block and served as a printing control and to define the blocks. Eight 
empty blocks were available to print additional antigens and relevant controls such as 
biotinylated BSA. Since all secretomics proteins have a 6-His tag and approximatively 1/3 
have an additional mouse Fc-tag, the printing efficiency of the proteins and microarray quality 
was evaluated by probing the microarrays with a mouse anti-His (Sigma H1029) antibody 
followed by a detection using a mix of a Cy5 conjugated F(ab’)2 goat a-mIgG Fc specific 
(Jackson IR 115-176-071 ) and a Cy5 conjugated goat a-hIgG F(ab')2 specific secondary 
antibody (Jackson IR 109-175-097). The last secondary antibody (Jackson IR 109-175-097) 
was systematically used in the assays to detect the human IgG control spots printed on the 
arrays in order to define the blocks. 4CMenB vaccine antigen NadA3, was biotinylated using 
EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific) following manufacturer's instruction. The 
mass of the proteins and degree of biotinylation was checked with Liquid chromatography 
coupled to mass spectrometry (LC-MS). The incubation of protein microarrays with NadA3 
was performed using an automated hybridization station (HS400; Tecan), programmed with 
an internal protocol. First, the protein microarrays were incubated with a PBS blocking 
solution containing 1% BSA and 0.1% Tween20 for 1 hour at 23 °C to reduce non-specific 
binding. Then, NadA3, diluted in probing buffer (2.5% glycerol, 1% BSA, and 0.05% TritonX 
in PBS) at final concentrations of 150 nM and 1 µM, were incubated for 1 h at 23 °C. After a 
washing step with probing buffer, the microarrays were probed with Cy5-Streptavidin 
(Invitrogen SA1011) combined with Cy5-goat a-hIgG F(ab')2 specific (Jackson IR 109-175-
097) diluted in probing buffer at 7.5 μg/ml final concentration. Finally, after two washing steps 
using probing buffer and Milli-Q water, the microarrays were dried under a flow of nitrogen at 
30 °C for 4 min. In parallel a control microarray slide probed with buffer and the mix of the 
detection antibodies was performed.  
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Microarray imaging and data analysis 
Microarray image acquisition was done using a fluorescence microarray scanner (GenePix 
Professional 4200A; Molecular Devices) equipped with a red laser (635 nm) at a resolution of 
10 μm/pixel and images were analyzed using the GenePix Pro v6.1 software (Molecular 
Devices). Data analysis was performed using in-house developed software. For each protein, 
the mean fluorescence intensity (MFI) of replicated spots was determined, after subtraction 
of the background value surrounding each spot. The MFI obtained for each protein was 
normalized by setting the MFI of the control biotinylated BSA to 100 %. Proteins with a high 
coefficient variation (CV) between the two replicates were discarded. All signals which were 
equal or greater than 25% were considered as positive hits, excluding the positive hits found 
in the control microarray where the Cy5-Streptavidin alone was probed to determine its 
unspecific reactivity to the printed proteins.  
NadA3 and NadA3 constructs cloning, expression, purification and 
characterization 
The nadA gene fragments from N. meningitidis strain 2996 were cloned by PCR, using the 
PIPE (polymerase incomplete primer extension) method, as described previously [10]. The 
cloned fragments lacked the first 23 residues of NadA which encode a signal peptide for 
protein export. The fragments were inserted into a pET-21 vector (Novagen), enabling 
cytoplasmic expression of the NadA proteins with a C-terminal 6-His tag. The residue 
numbering employed refers to the full-length NadA protein, Uniprot code Q8KH85. All NadA 
proteins were produced in Escherichia coli BL21D3 (T1r) cells (Invitrogen) and were purified 
at room temperature (RT, 18-26°C) using an AKTA purifier 10 system (GE Healthcare) by Ni-
affinity chromatography (5mL HiTrap Ni-NTA column) and by size-exclusion chromatography 
on a HiLoad (16/60) Superdex 75 column equilibrated in 20 mM Tris–HCl, 150 mM NaCl 
pH8.0. The quality of the final NadA samples was checked using 4–12% SDS–PAGE 
gradient gels in MES buffer and also by size-exclusion high-performance liquid 
chromatography (SE-HPLC), revealing a high level of purity (estimated to be >97% for all 
proteins) and a lack of any aggregated species. SE-HPLC was performed at RT on an 
analytical size exclusion TSK Super SW3000 column by loading 20μl of each sample at a 
concentration of ~ 40μM. Samples were eluted isocratically in 0.1M NaH2PO4, 0.4M 
(NH4)2SO4 buffer at pH 6.0. Coupling SE-HPLC with Multi-angle laser light scattering (SE-
HPLC/MALLS) NadA samples were analyzed for molecular size. Data analyses were carried 
out using Astra V software (Wyatt) to determine the weight-average molecular mass (MW) in 
Daltons and the polydispersity index (MW/Mn) for each oligomer present in solution. 
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BioLayer Interferometry (BLI)-based OCTET assay  
Octet QKe (ForteBio, Pall Science) was used for binding studies. SA (streptavidin) and 
AR2G (amine reactive 2nd generation) tips were obtained from ForteBio and were used 
respectively to immobilize biotinylated proteins and to covalently attach ligand protein using 
amine based chemistry. Immediately before analysis, tips were pre-wet in kinetic buffer 
(10mM HEPES, 150mM NaCl, 0,02% P-20 pH 7.4). After 180 sec baseline, AR2G tips were 
activated for 300 sec using a freshly mixed solution of 200 mM EDC in 50 mM NHS further 
diluted 1:20 in dH2O. The tips were then immersed in ligand solution (LOX-1 at 12.5µg/ml in 
acetate pH 5.5) for 600 sec. Excess reactive groups were blocked with 1 M ethanolamine pH 
8.5 for 300 sec and a second 300 sec baseline in kinetic buffer was performed. Association 
and dissociation were monitored. For SA biosensor, after 180 sec baseline, tips were directly 
immersed in ligand solution for 600 sec loading (biotinylated NadA3, NadA324-170 and 
NadA391-342 at 25µg/ml in kinetic buffer) and a second 300 sec baseline in kinetic buffer was 
performed. Kinetic was then monitored. During the entire kinetic assay the sample plate was 
kept shaking 1000rpm. A column of biosensors where no ligand protein was loaded, was 
activated and quenched to be used as parallel reference control in association with the 
analyte titration; a ligand-loaded biosensor was also used in association with buffer as 
baseline.  
Reference subtracted BLI response curves were used for the affinity constant determination. 
Inter-step correction and Y-alignment were used to minimize tip-dependent variability. Data 
were globally fit in a 1:1 model using the Data Analysis Software v7.1 (Forte Bio).  
 
Dynamic Light Scattering (DLS) measurements 
For DLS analysis DynaPro® Plate Reader II (WYATT Technology) with 96 Well Plates was 
used. NadA3, LOX-1 and the complex midex in a 1:1 ratio were diluted in HBS-P buffer in a 
final concentration of 5 µM. A cut off from 0,1 to 100nm was applied. results are mean of 30 
measurements per sample.  
 
mAbs and Fabs selection and binding competiton 
For competition experiments, a preliminary screening to select high-affinity anti-NadA3 mAbs 
and Fabs was performed. Protein G biosensors tips were pre-wet in kinetic buffer (10mM 
HEPES, 150mM NaCl, 0,02% P-20 pH 7.4). After 180 sec baseline, tips were directly 
immersed in each mAb (diluted at 50 µg/ml in kinetic buffer) for 600 sec. A second 300 sec 
baseline in kinetic buffer was performed. NadA3 was tested as analyte at 200 nM. 
Competition experiments were performed immobilizing LOX-1 as above. NadA3 was pre-
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incubated with an excess of mAb (1:3) overnight at 4°C and the mix was used as analyte in 
the same assay conditions as above. 
 
FACS binding experiments  
To perform binding assay, LOX-1 transfected and non-transfected CHO cells were detached 
using trypsin (CDS, Sigma), harvested and suspended in F12-K medium supplemented with 
10% FBS. Approximately 1 x 106 cells were incubated with 200 µg/ml NadA or PBS alone for 
30 minutes at 4°C. Cells were then incubated with 5 µg/ml of anti-NadA 9F11 mouse 
monoclonal antibody for 1 hour at 4°C, and with Allophycocyanin (APC)-conjugated goat 
F(ab)2 anti-mouse Ig (diluted 1:100; Jackson ImmunoResearch Laboratories) for 30 minutes 
at 4°C. Cells were stained with Live/Dead Aqua (Invitrogen) diluted 1:400 for 20 minutes in 
the dark and analyzed with a Canto II analyzer (Becton Dickinson, Pharmingen, San Diego, 
CA). Flow-cytometric analysis was performed using FlowJo software (Treestar Inc.).  
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Results 
Microarray Screening for NadA3 interactors 
In order to identify human proteins interacting with the Neisseria meningitidis adhesin A 
(NadA), an important component of the Bexsero® vaccine [16], a large scale protein 
microarray screening was performed. The protein array was built spotting 2354 human 
recombinant proteins selected and produced as previously described [15]. Briefly, starting 
from previous large scale efforts and additional bioinformatic analysis, the gene coding for 
the ectodomain of 2687 human proteins were cloned in plasmid for transient transfection, 
expressed with affinity tags (6xHis and FLAG) in HEK293 cells and purified in high-
throughput way. The NOV-GNF microarrays were validated using anti-His and anti-mouse 
antibodies showing that 71% of the proteins were detected, thus correctly printed and 
immobilized onto the slides. The interaction of the biotinylated NadA3 to printed proteins was 
detected using fluorescently labeled streptavidin. Internal control biotinylated BSA spots were 
taken as reference signal (100% signal) and the mean fluorescence intensities (MFI) of all 
duplicate spots were normalized and indicated as percentage of the reference. An arbitrary 
threshold of 25% of the reference signal was defined in order to select relevant interactions. 
Biotinylated NadA3FL (NadA3 Full length protein) was first used in overlay at 150 nM. The 
resulting screening showed several putative human interactors  (figure 3.1A). Isoform 1 and 
2 of the Vasoactive Intestinal Peptides (VIP) with an MFI score of 153% and 60% 
respectively and the Protein Tyrosine Phosphatase Receptor type Sigma isoform 4 (PTPRS) 
with an MFI of 64% were highlighted as strong hits. Two replicates of the low-density 
oxidized lipoprotein (lectin-like) receptor 1 (LOX-1) with a MFI score of 45% and 37% 
represent potentially relevant hits. These data were substantiated when NadA3 was tested at 
1 µM. All five hits identified in the 150 nM screen could be confirmed (figure 3.1B). In 
addition to these proteins, further putative hits were identified: the Stromal interaction 
molecule 1 precursor (STIM1, MFI 54%), the Natriuretic Peptide Precursor C (NPPC, MFI 
30%), the hypothetical protein LOC122258 precursor (MFI, 27%) and the Interleukin 6 
precursor (IL-6, MFI 26%). 
Among all the identified hits, LOX-1 represented an interesting candidate for further 
validation processes since it is known to be involved in bacterial adhesion and invasion [17, 
18], endotoxin-induced inflammation [19] and its deletion enhances bacterial clearance in a 
murine polymicrobial sepsis model [20]. 
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NadA3 binds LOX-1 through its head&neck region 
Based on the protein array results, the NadA3–LOX-1 interaction was validated and 
characterized by label-free methods. In vitro binding experiments were performed using 
Figure 3.1 Screening for NadA3 interactors. (A) Plotting of MFIs relative percentage of spotted 
human proteins tested against NadA3FL at 150nM and (B) 1µM. Red bars represent human proteins 
above the 25% cut-off threshold defining relevant interactions. Blue bars represent human proteins 
above the 4% cut-off threshold. Inset table shows gene symbol, protein name and MFI values of the 
relevant interactions  
A 
B 
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BioLayer Interferometry (BLI). LOX-1 recombinant protein was first immobilized onto the BLI 
biosensor using amine reactive chemistry and NadA3FL was tested in serial dilutions as 
analyte showing dose dependency (figure 3.2A). The calculated affinity using a 1:1 fitting 
model was 57nM. This value was also confirmed when the system was inverted and LOX-1 
was used as analyte on immobilized NadA3FL. An affinity constant of 60nM was indeed 
calculated (figure 3.2B). DLS analysis was carried out to determine the interaction in 
solution (figure 3.2C): the proteins were first analyzed alone, resulting in a hydrodynamic 
radius of 4.2 nm and 6.2 nm for LOX-1 and NadA3FL, respectively, and then analyzed as 
mix in a 1:1 ratio, resulting in a single peak with hydrodynamic radius of 8.9 nm and low 
polydispersity index, i.e. 13.4%. The peaks corresponding to the single proteins were not 
detected, indicating s complete involvement of the proteins in complex formation.  
 
A 
B 
NadA FL (3.2 - 0.2 µM) to LOX-1  
KD = 57.6 ± 4.3 nM 
LOX-1 (500 - 15 nM) to NadA FL 
KD = 60.6 ± 2.7 nM 
Figure 3.2 Binding of NadAFL to LOX-1 was validated through BioLayer Interferometry and 
DLS. (A) Blank subtracted sensograms of NadA3FL (3.2 – 0.2µM) tested on covalently immobilized 
LOX-1 and (B) of LOX-1 (500 - 15 nM) tested on biotinylated NadA3FL immobilized on SA biosensors. 
Association and dissociation curves were fitted in a 1:1 model. (C) DLS analysis of NadA3FL, LOX-1 
and the complex. Results are mean of 30 measurements. The hydrodynamic radius of LOX-1, NadA3 
and their complex were 4.2 nm, 6.2 nm and 8.9 nm, while the calculated MW were 97KDa, 242KDa 
and 565KDa respectively. Sample polydispersity is also shown in table.  
 
C 
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To identify the binding region for LOX-1, the NadA324-170 (head&neck) and NadA391-342 (stalk) 
constructs were designed based on the recently published crystal structure [10] and 
produced as his-tagged recombinant proteins (figure 3.3A). SE-HPLC/MALLS showed a 
measured MW of 52KDa and 87KDa for NadA324-170 and NadA391-342 respectively, confirming 
the expected MW of the trimeric constructs (figure 3.3B). Octet BLI binding experiments 
performed using biotinylated NadA3 constructs as ligand and LOX-1 as analyte, revealed the 
retained capability of the NadA324-170 construct to bind LOX-1. The binding was instead 
abolished in the NadA391-342 construct (figure 3.3C). The calculated affinity between 
NadA324-170 and LOX-1 was in the pM range (figure 3.3D). 
 
A 
B 
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Anti-head mAbs inhibits NadA-LOX-1 binding 
In order to understand the potential ability of anti-head monoclonal antibodies (mAbs) to 
inhibit the NadA-LOX-1 binding, competition experiments using Octet BLI were performed. 
Anti-NadA3 mAbs were first selected based on their binding site on NadA3 using protein 
microarray and Biacore binding experiments (in house data - not shown). Additional KD 
ranking experiments were used to select high affinity anti-NadA3 mAb (table 1).  
 
 
 
 
Loading Sample ID Binding site on NadA3 KD (M) 
9F11 stalk (269-316) 1,02E-09 
1C9/A9 head (24-107) 1,61E-10 
8D9/A9 head (24-107) 2,51E-10 
3C11/H7 head (1-235) 1,63E-09 
Table 3.1 mAbs KD ranking. Name, binding site and KD of the antibodies used in the competition 
assay are reported. 
LOX-1  500nM to NadA3 constructs 
NadA3 FL 
NadA391-342 
NadA324-170  
LOX-1 (250 - 7.8 nM) to NadA324-170  
KD < 1.2 ρM 
Figure 3.3 Characterization and binding experiments of the NadA3 24-170 and NadA3 91-342 
constructs. (A) Schematic representation of the NadA3 constructs used to determine NadA3 binding 
site on LOX-1. NadA3 gene, NadA324-342 (green), NadA324-170 (blue) and NadA391-342 (yellow) structure 
are shown. Signal peptide (light blue) and membrane anchor (orange) are shown in the cartoon. (B) 
SEC-HPLC/MALLS measurements of the NadA324-170 (left) and NadA391-342 (right). Light Scattering 
(LS - red), UV (green), and refractive index (RI - blue) signals are shown. Inset table and box shows 
respectively the calculated MW and the sample polydispersity. (C) Blank subtracted sensograms of 
LOX-1 (200nM) on biotinylated NadA324-342 (blue), NadA324-170 (red) and NadA391-342 (light blue). (D) 
Blank subtracted sensograms of LOX-1 (125 – 7.8 nM) tested on biotinylated NadA324-170. Binding 
curves were fitted in a 1:1 model. 
C 
D 
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For competition tests, LOX-1 was covalently immobilized on biosensor surface and NadA3 
pre-incubated with mAb was used as analyte. BLI binding assay (figure 3.4) showed a 
marked ability of mAb mapping the NadA3 head region (24-170) to inhibit the binging with 
LOX-1. By contrast mAb 9F11, mapped on NadA3 stalk region (269-316), did not inhibit the 
binding confirming the data obtained with NadA3 constructs. 
 
NadA binds CHO cells expressing hLOX-1 
To further validate the interaction between LOX-1 and NadA3, binding assays in eukaryotic 
cell lines were performed. CHO (Chinese Hamster Ovary) cell line was chosen since does 
not express human LOX-1 constitutively (data not shown). CHO cells were transfected with a 
pEYFP-N1 vector containing LOX-1 cDNA and the expression was tested by FACS analysis. 
When transfected, the LOX-1 expressing cell population is the 32.9% of the total, while, as 
expected, no protein expression was detected on non-transfected cells. The binding with 
NadA3 was monitored after incubation of the protein with the transfected and non-transfected 
cells (negative control). NadA3 can bind only the LOX-1 transfected cell population, while 
non-transfected cells did not show any binding, confirming the results obtained with label-free 
technologies (figure 3.5). 
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NadA3 200nM + mAbs to LOX-1 constructs 
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NadA3FL + mAb 9F11 
NadA3FL +  mAb 3C11 
NadA3FL + mAb 1C9 
 
NadA3FL + mAb 8D9 
 
Figure 3.4 Blank subtracted sensograms of NadA incubated with mAbs or Fabs on covalenty 
immobilized LOX-1. Binding between NadA3 and LOX-1 is shown (red). mAb 9F11 mapping NadA3 
stalk does not inhibit the binding with NadA3 (blue). mAb 3C11/H7 (violet), mAb 1C9/A9 (light blue) 
and mAb 8D9/A9 (green) mapping on NadA3 head abrogated NadA3 binding on LOX-1. 
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Figure 3.5 NadA binds CHO cells expressing hLOX-1. FACS plots representative of LOX-1 (YFP) 
expression in CHO cells and cells able to bind NadA (APC). The gating strategy was designed to 
separate the cells of interest from large aggregates and debris [initial gate on forward scatter (FSC) 
versus side scatter (SSC) plot], deplete dead cells (Live/Dead Aqua staining) and doublets/aggregates 
(standard gates on both FSC-width and SSC-width) (data not shown). Simple gating by quadrants 
allowed defining the absolute percentages of cells positive for LOX-1 only (32%, bottom left) and 
double positive cells (30%, bottom right) representing the cells able to bind recombinant NadA. The 
upper right panel shows that not-transfected cells are not able to bind NadA if incubated with the 
recombinant protein. The upper left panel shows the non-transfected cells. 
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Discussion 
Neisseria meningitidis is a pathogenic bacteria and a leading cause of meningitis and 
bacterial sepsis in the world. Twelve strains are known but the most aggressive and infective 
are caused by serogroups A, B, C, X, W-135 and Y. Carbohydrate based vaccines are 
already available for the A, C, W, Y strains [3]. Due to structural similarities between the 
capsular polysaccharides of the type B with the neuraminic acid present on the surface of 
human fetal neural tissues, the development of a vaccine against the type B needed a 
protein-based approach. In 2013 the first recombinant 4 component vaccine against MenB 
(4CMenB) was released [7]. One of the components is the neisserial adhesin A (NadA) 
protein, a trimeric coiled coil adhesin whose structure was recently solved [10]. Several 
functional studies indicated NadA as an important adhesion factor, and key effector in 
pathogenesis [21, 22]. Despite the structural and functional information a global picture of 
human receptors targeted by NadA has remained unknown.  
The microarray format is an ideal high throughput technology for analyzing multiple protein-
protein interaction in parallel. The NOV-GNF protein microarray is a unique platform 
constituted with a large collection of human secretomics proteins. An internal experimental 
protocol was developed to analyze protein-protein interactions in case of NadA3 where the 
lack of definitive positive control (i.e known interacting proteins for NadA3) added another 
level of uncertainty to set the analysis threshold. The fact that positive biotinylated BSA 
control printed on the slides probed with only Cy5-Streptavidin secondary detection worked 
well testified that experimental conditions (e.g. buffer, composition, temperature, pH, salts, 
concentrations, etc.) were favorable. An arbitrary threshold of 25% of the reference signal 
(biotinylated BSA control signal) was defined in order to select the most significant 
interactions. However, is it possible that many of the protein-protein interactions are weak in 
nature yet biologically meaningful. Moreover, there is no guarantee all proteins retain their 
secondary and tertiary structure when immobilized or their biological activity.  
The screening was performed using biotinylated NadA3 at two concentrations and lead to the 
identification of several human putative interactors. The hits resulted from the screening 
using NadA3 at 150nM were two isoforms of the VIP (Vasoactive Intestinal Peptides), LOX-1 
(low-density oxidized lipoprotein lectin-like receptor 1) and PTPRS (Protein Tyrosine 
Phosphatase Receptor type Sigma isoform 4). The vasoactive intestinal peptides were 
shown to be involved in vasodilation, relaxation of the smooth muscle of trachea, stomach 
and gall bladder [23]. In addition VIP were already described to protect, through the inhibition 
of protein kinase C (PKC) activity, against epithelial barrier disruption and colitis caused by 
bacterial pathogen like EPEC (enteropathogenic Escherichia coli) [24]. PTPRS was instead 
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described in neuronal development and as a positive regulator of intestinal epithelial barrier. 
It modulates epithelial cells adhesion targeting proteins associated with apical junction 
complex [25]. This might drive to epithelial cell relaxation facilitating bacterial permeation. 
LOX-1 is the receptor for oxidized low-density lipoproteins and it is implicated in the 
pathogenesis of different diseases, including atherosclerosis, hypertension, obesity, diabetes 
mellitus and metabolic syndrome [26-28]. It was identified as a OxLDL receptor primarily in 
endothelial cells and it was described to be involved in OxLDL internalization [29]. Several 
studies already demonstrated the role of LOX-1 in bacterial adhesion to endothelial cells. 
Shimaoka et al. described Staphylococcus aureus and Escherichia coli to be able to bind 
CHO cells transfected with LOX-1 [17]. The binding was abrogated with anti-LOX-1 
antibodies. Further studies demonstrated that the infection of endothelial cells by Chlamydia 
pneumoniae is inhibited by ligands that bind to LOX-1. Also in this case both the binding of 
C. pneumoniae on endothelial cells and its infectivity were inhibited by anti-LOX-1 antibodies 
[18]. It was also shown that LOX-1 deletion in mice improves neutrophil responses, 
enhances bacterial clearance, and reduces lung injury [20]. STIM1 (Stromal interaction 
molecule 1 precursor), NPPC (Natriuretic Peptide Precursor C), the hypothetical protein 
LOC122258 precursor and IL-6 (Interleukin 6 precursor) were instead revealed only in the 
screening performed using NadA3at 1µm, possibly meaning a lower affinity for NadA if 
compared to the previous hits, which were all confirmed. STIM1 was described to play a role 
in mediating cellular store-operated Ca2+ entry (SOCE), by acting as Ca2+ sensor in the 
endoplasmic reticulum via its EF-hand domain. This leads the protein to be involved in 
several cellular functions, like microtubules remodeling and phagocytes and T-cell activation 
[30-32]. Moreover this receptor was previously described to be involved in bacterial and viral 
pathogenesis. The Clostridium difficile transferase toxin (CTD) induces microtubule-based 
protrusions in human coloncarcinoma (Caco-2) cells, and increases pathogen adherence 
through STIM1. The toxin reroutes Rab11-positive vesicles containing fibronectin, which is 
involved in bacterial adherence, from basolateral to the apical membrane sides in a 
microtubule- and STIM1-dependent manner [33]. The rotavirus nonstructural protein 4 
(NSP4) was also shown to be involved in changes in cellular calcium homeostasis through 
STIM1 activation, which was constitutively active in rotavirus-infected cells [34]. In a similar 
way, Streptolysin O (SLO) from Group A Streptococcus induces diverse types of Ca(2+) 
signaling in host cells including Ca(2+) release from intracellular stores in a STIM1-
dependent way [35]. NPPC or CNP (C-type natriuretic peptide) is part of the natriuretic 
hormones (NH), a class which includes three groups of compounds: the natriuretic peptides 
(ANP, BNP and CNP), the gastrointestinal peptides (guanylin and uroguanylin), and 
endogenous cardiac steroids. These substances stimulate the kidney to excrete sodium and 
therefore have a function in the regulation of sodium and water homeostasis, blood volume, 
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and blood pressure [36]. In addition they were also described to act as neurotransmitters or 
neuromodulators in the brain [37, 38]. CNP was also described to be involved in bacterial 
virulence and toxin production in host environment by Pseudomonas aeruginosa, enhancing 
its virulence [39]. It was shown that P. aeruginosa is sensitive to natriuretic peptides through 
a cyclic nucleotide-dependent sensor system. A pre-treatment of P. aeruginosa with CNP 
was shown to increase the capacity of the bacteria to kill Caenorhabditis elegans through 
diffusive toxin production. In contrast, brain natriuretic peptide (BNP) did not affect the 
capacity of the bacteria to kill C. elegans. The hypothetical protein LOC122258 (c13orf28) 
also called SPACA7 (Sperm acrosome-associated protein 7) was recently shown to be a 
novel male germ cell-specific protein localized on the sperm acrosome, but its involvement in 
bacterial pathogenesis was never described and it's not easy to find a relationship with 
NadA3 role in adhesion and invasion. IL-6 (Interleukin 6) is a cytokine with a wide variety of 
biological functions and plays an essential role in the final differentiation of B-cells into Ig-
secreting cells. It is also involved in lymphocyte and monocyte differentiation. IL-6 is involved 
in response to pathogens and it was shown to down-regulate the activation of the cytokine 
network in the lung and contributes to host defense during pneumococcal pneumonia [40]. 
Within the identified hits, LOX-1 among the others constituted a potentially remarkable hit for 
further characterization since it was the only endothelial receptor identified in the screening. 
In addition, the interaction between NadA3 and an endothelial receptor as never been 
described before and it may constitute a key feature in the understanding of N. meningitidis 
pathogenesis. Binding experiments using Octet BLI confirmed the interaction between 
NadA3 and LOX-1 showing a KD of ~60nM in both the binding orientations. This data was 
also confirmed by DLS analysis which showed the complex is formed also in solution. The 
hydrodynamic radius and the calculated MW of both NadA3FL, LOX-1 and the complex is 
actually much larger than the expected based on calculations carried out on globular 
proteins. This discrepancy can be easily explained by the rod-shaped structure of the 
proteins as well as, for the NadA3-LOX-1 complex, by the possible head-to-head interaction, 
as also suggested by the constructs tested in BLI. In fact, experiments carried out using 
NadA3 stalk (91-342) and head&neck (24-170) constructs identified the latter as the major 
binding region. A KD measurement of the NadA324-170 construct on LOX-1 revealed an affinity 
much higher than the full-length protein. This effect was not investigated further, however it 
seems to suggest that the decreased steric hindrance of NadA324-170 construct compared to 
NadA3FL leads to a faster accessibility of LOX-1 for the ligand. The identification of NadA3 
head as the binding region for LOX-1 was also confirmed by competition experiments using 
anti-NadA3 mAbs. All the tested mAbs targeting NadA3 head (24-170) showed competition 
with LOX-1 for NadA binding, while the mAb 9F11 mapping on NadA stalk (269-316) showed 
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higher binding intensity if compared with NadA3 alone. This effect is probably due to an 
increased mass of NadA3 complexed with 9F11 which results in higher interference, and 
thus in higher signal in BLI. The binding between LOX-1 and NadA3 was further corroborated 
by cellular binding assay. Despite the low level of LOX-1 transfection (32.9%), all the CHO 
cells transiently expressing LOX-1 showed binding with recombinant NadA3, confirming the 
binding happens also on cell surface.  
The identification and biophysical validation of an endothelial receptor, among the others, for 
NadA3 constitutes an additional value for the understanding of N. meningitidis pathogenesis. 
Further studies will be necessary to clarify NadA role in endothelium binding, in order to 
understand if it can contribute in endothelial crossing, being for this reason responsible in 
crucial mechanisms like blood-brain barrier crossing and meningitis development.  
LOX-1 is the endothelial receptor for NadA Chapter THREE 
 
EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 71 
 
 
References 
 
1. Pace, D. and A.J. Pollard, Meningococcal disease: clinical presentation and 
sequelae. Vaccine, 2012. 30 Suppl 2: p. B3-9. 
2. Rouphael, N.G. and D.S. Stephens, Neisseria meningitidis: biology, microbiology, 
and epidemiology. Methods Mol Biol, 2012. 799: p. 1-20. 
3. Pace, D., A.J. Pollard, and N.E. Messonier, Quadrivalent meningococcal conjugate 
vaccines. Vaccine, 2009. 27 Suppl 2: p. B30-41. 
4. Finne, J., et al., An IgG monoclonal antibody to group B meningococci cross-reacts 
with developmentally regulated polysialic acid units of glycoproteins in neural and 
extraneural tissues. J Immunol, 1987. 138(12): p. 4402-7. 
5. Black, S., et al., Toward a meningitis-free world. Sci Transl Med, 2012. 4(123): p. 
123ps5. 
6. Rosenstein, N.E., et al., Meningococcal disease. N Engl J Med, 2001. 344(18): p. 
1378-88. 
7. Pizza, M., et al., Identification of vaccine candidates against serogroup B 
meningococcus by whole-genome sequencing. Science, 2000. 287(5459): p. 1816-
20. 
8. Serruto, D., et al., The new multicomponent vaccine against meningococcal 
serogroup B, 4CMenB: immunological, functional and structural characterization of 
the antigens. Vaccine, 2012. 30 Suppl 2: p. B87-97. 
9. Comanducci, M., et al., NadA diversity and carriage in Neisseria meningitidis. Infect 
Immun, 2004. 72(7): p. 4217-23. 
10. Malito, E., et al., Structure of the meningococcal vaccine antigen NadA and epitope 
mapping of a bactericidal antibody. Proc Natl Acad Sci U S A, 2014. 111(48): p. 
17128-33. 
11. Capecchi, B., et al., Neisseria meningitidis NadA is a new invasin which promotes 
bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol, 2005. 
55(3): p. 687-98. 
12. Tavano, R., et al., Mapping of the Neisseria meningitidis NadA cell-binding site: 
relevance of predicted {alpha}-helices in the NH2-terminal and dimeric coiled-coil 
regions. J Bacteriol, 2011. 193(1): p. 107-15. 
13. Cecchini, P., et al., The soluble recombinant Neisseria meningitidis adhesin 
NadA(Delta351-405) stimulates human monocytes by binding to extracellular Hsp90. 
PLoS One, 2011. 6(9): p. e25089. 
14. Nagele, V., et al., Neisseria meningitidis adhesin NadA targets beta1 integrins: 
functional similarity to Yersinia invasin. J Biol Chem, 2011. 286(23): p. 20536-46. 
15. Gonzalez, R., et al., Screening the mammalian extracellular proteome for regulators 
of embryonic human stem cell pluripotency. Proc Natl Acad Sci U S A, 2010. 107(8): 
p. 3552-7. 
16. Giuliani, M.M., et al., A universal vaccine for serogroup B meningococcus. Proc Natl 
Acad Sci U S A, 2006. 103(29): p. 10834-9. 
17. Shimaoka, T., et al., LOX-1 supports adhesion of Gram-positive and Gram-negative 
bacteria. J Immunol, 2001. 166(8): p. 5108-14. 
18. Campbell, L.A., et al., Chlamydia pneumoniae binds to the lectin-like oxidized LDL 
receptor for infection of endothelial cells. Microbes Infect, 2012. 14(1): p. 43-9. 
Chapter THREE LOX-1 is the endothelial receptor for NadA 
 
72 EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 
 
 
19. Honjo, M., et al., Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule 
involved in endotoxin-induced inflammation. Proc Natl Acad Sci U S A, 2003. 100(3): 
p. 1274-9. 
20. Wu, Z., et al., LOX-1 deletion improves neutrophil responses, enhances bacterial 
clearance, and reduces lung injury in a murine polymicrobial sepsis model. Infect 
Immun, 2011. 79(7): p. 2865-70. 
21. Bozza, G., et al., Role of ARF6, Rab11 and external Hsp90 in the trafficking and 
recycling of recombinant-soluble Neisseria meningitidis adhesin A (rNadA) in human 
epithelial cells. PLoS One, 2014. 9(10): p. e110047. 
22. Montanari, P., et al., Human heat shock protein (Hsp) 90 interferes with Neisseria 
meningitidis adhesin A (NadA)-mediated adhesion and invasion. Cell Microbiol, 2012. 
14(3): p. 368-85. 
23. Yiangou, Y., et al., Isolation, characterization, and pharmacological actions of peptide 
histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide. J Biol 
Chem, 1987. 262(29): p. 14010-3. 
24. Morampudi, V., et al., Vasoactive Intestinal Peptide Prevents PKCepsilon-Induced 
Intestinal Epithelial Barrier Disruption During EPEC Infection. Am J Physiol 
Gastrointest Liver Physiol, 2014: p. ajpgi 00195 2014. 
25. Murchie, R., et al., Protein tyrosine phosphatase sigma targets apical junction 
complex proteins in the intestine and regulates epithelial permeability. Proc Natl Acad 
Sci U S A, 2014. 111(2): p. 693-8. 
26. Kita, T., et al., Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci, 2001. 947: 
p. 199-205; discussion 205-6. 
27. Kita, T., et al., Oxidized-LDL and atherosclerosis. Role of LOX-1. Ann N Y Acad Sci, 
2000. 902: p. 95-100; discussion 100-2. 
28. Mehta, J.L., et al., Inhibition of LOX-1 by statins may relate to upregulation of eNOS. 
Biochem Biophys Res Commun, 2001. 289(4): p. 857-61. 
29. Sawamura, T., et al., An endothelial receptor for oxidized low-density lipoprotein. 
Nature, 1997. 386(6620): p. 73-7. 
30. Honnappa, S., et al., An EB1-binding motif acts as a microtubule tip localization 
signal. Cell, 2009. 138(2): p. 366-76. 
31. Shaw, P.J., et al., CD4(+) and CD8(+) T cell-dependent antiviral immunity requires 
STIM1 and STIM2. J Clin Invest, 2014. 124(10): p. 4549-63. 
32. Zhang, H., et al., STIM1 calcium sensor is required for activation of the phagocyte 
oxidase during inflammation and host defense. Blood, 2014. 123(14): p. 2238-49. 
33. Schwan, C., et al., Clostridium difficile toxin CDT hijacks microtubule organization and 
reroutes vesicle traffic to increase pathogen adherence. Proc Natl Acad Sci U S A, 
2014. 111(6): p. 2313-8. 
34. Hyser, J.M., et al., Activation of the endoplasmic reticulum calcium sensor STIM1 and 
store-operated calcium entry by rotavirus requires NSP4 viroporin activity. J Virol, 
2013. 87(24): p. 13579-88. 
35. Usmani, S.M., et al., Molecular basis of early epithelial response to streptococcal 
exotoxin: role of STIM1 and Orai1 proteins. Cell Microbiol, 2012. 14(3): p. 299-315. 
36. Marin-Grez, M., J.T. Fleming, and M. Steinhausen, Atrial natriuretic peptide causes 
pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. 
Nature, 1986. 324(6096): p. 473-6. 
37. Komatsu, Y., et al., C-type natriuretic peptide (CNP) in rats and humans. 
Endocrinology, 1991. 129(2): p. 1104-6. 
LOX-1 is the endothelial receptor for NadA Chapter THREE 
 
EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 73 
 
 
38. Hodes, A. and D. Lichtstein, Natriuretic hormones in brain function. Front Endocrinol 
(Lausanne), 2014. 5: p. 201. 
39. Blier, A.S., et al., C-type natriuretic peptide modulates quorum sensing molecule and 
toxin production in Pseudomonas aeruginosa. Microbiology, 2011. 157(Pt 7): p. 1929-
44. 
40. van der Poll, T., et al., Interleukin-6 gene-deficient mice show impaired defense 
against pneumococcal pneumonia. J Infect Dis, 1997. 176(2): p. 439-44. 
 
  
Chapter THREE LOX-1 is the endothelial receptor for NadA 
 
74 EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 
 
 
  
  
 
 
 
 
 
Chapter FOUR 
 
 
Protein microarrays and validation technologies for 
protein-protein interaction studies: pros and cons 
 
 
  
Chapter FOUR Protein microarray and validation technologies for PPI studies 
 
76 EXPLORING HOST-PATHOGEN INTERACTIONS THROUGH PROTEIN MICROARRAY 
 
 
Introduction 
Cellular processes take place thanks to wide and extended networks of protein-protein 
interactions (PPIs) [1]. It is therefore not surprising that with the advance of -omics 
approaches like proteomics, genomics, transcriptomics and secretomics the map of the 
interactome, constituted by all the protein-protein interactions identified within a cellular 
process or compartment, is in exponential increase. The complete map of interaction 
partners of a protein is critical to understand its function and the cellular process in which it 
takes part within a cell [2]. Among the incredible number of processes based on protein-
protein interactions, host-pathogen interactions represent a key research topic that can help 
to gain a deeper understanding of molecular mechanism underlying pathogenesis and 
therefore support an easier and faster identification and development of efficient therapies 
against pathogenic bacteria. The basic idea which lies beneath this statement is the 
increasing evidence that surface-exposed bacterial proteins known to target human immune 
components can possibly constitute good vaccine candidates against that pathogen. Indeed, 
antibodies elicited against such bacterial proteins have been shown to act in two ways: they 
mediate direct bacterial lysis through complement activation; and they prevent binding of the 
immune evasion molecule to its human target, therefore increasing bacterial susceptibility 
within the host. This is the case for fHbp, a constituent of the 4cMenB vaccine (four 
component meningococcus B vaccine) that is able to elicit bactericidal antibodies [3-5]. 
Exploring host-pathogen interactions for these reasons is a precious resource for both 
scientific and medical community.  
Usually, the identification of novel host-pathogen interactions involves an initial 
medium/large-scale screening, which will hopefully results in the identification of several 
potential partners for the protein(s) under investigation. Plenty of techniques have been 
developed for this purpose. Among all, protein microarray is well established and it will be 
described in detail in this chapter. This technique has several advantages and in the same 
way different disadvantages, which will also be discussed in the following pages. 
The hits derived from the initial screening must be validated to increase the reliability and 
confidence of the data generated. Indeed, a deep and accurate statistical analysis and/or a 
downstream experimental validation are required. The lab-based validation of such kind of 
PPI screening is usually performed through the use of label-based or label-free techniques to 
confirm and better characterize the interaction. In the past years, thanks to technical 
advances in optics, several label-free instruments have become the gold standard for PPI 
validation. In particular, SPR (surface plasmon resonance) and more recently BLI (BioLayer 
interferometry) are widely used for hit validation and characterization. In addition to these 
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techniques, the increasing need of simultaneous screening and characterization, led to the 
development of hybrid instruments like SPRi (Surface Plasmon Resonance Imaging) 
designed in a way that the advantages of label-free techniques are combined with the higher 
throughput of the screening methodologies. A description of this technique will also be part of 
this chapter.  
 
Screening technologies 
The first step in the identification of novel protein-protein interactions is constituted by 
methods that allow the identification of potential interactors of a protein under investigation. A 
lot of techniques have been developed, each one with different throughputs as well as 
different pros and cons. the Yeast two hybrid system (Y2H), co-immuno-precipitation, affinity 
chromatography, protein-fragment complementation, phage display, TAP-MS and protein 
microarrays are the most used and consolidated in literature. Y2H, protein fragment 
complementation, phage display and protein microarray are usually used for binary PPI 
identification and require a laborious process of construct and clone preparation (followed by 
protein purification in the case of microarrays) since large libraries are usually required to 
obtain satisfactory results. In contrast, co-immuno-precipitation, affinity chromatography and 
TAP-MS are used for macro-complexes identification and usually require few construct 
preparations which then are tested against a complex mixture of proteins such as biological 
fluids, cell culture supernatants, whole cell preparations or cell compartments.  
Protein microarrays 
Protein microarray is an emerging screening technology that constitutes a flexible tool for 
large scale PPI screenings. It allows indeed the simultaneous screening of thousands of 
proteins in a parallel and high-throughput way. Protein microarray usually consists of  purified 
proteins or antibodies (or DNA, RNA, peptides or glycans for other purposes than PPI 
discovery) immobilized on a small surface to build an array resembling a miniaturized ELISA 
plate. Despite the wide panel of diverse configurations that can be used, three major classes 
of protein microarrays are defined: analytical, functional and reverse-phase protein 
microarrays [6, 7]. 
Analytical protein microarrays 
In the analytical protein microarray, the affinity or capture agent is immobilized onto the solid 
array surface and incubated with the test sample (figure 4.1A). The most representative 
model of analytical protein microarrays is the antibody array in which a panel of antibodies is 
immobilized and tested with an antigen and vice versa. In this conformation the analyte is 
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usually labeled with a fluorescent dye for the detection. Several other immobilization formats 
have been described, among which the "sandwich" format is the most well known. The 
“sandwich” format exploits two different antibodies to detect the targeted protein [8, 9]. One is 
the capture antibody, which is immobilized on the microarray chip, while the reporter 
antibody is usually fluorescent-labeled,  generating a signal when it binds to the captured 
target protein.  
 
Figure 4.1 The three main categories of protein microarrays. (A) Analytical protein microarrays are 
mainly characterized by antibody arrays. A direct (left) or indirect (center) detection can be used. A 
reporter antibody is used to create a "sandwich" format (right). (B) Functional protein microarrays have 
broad applications in studying protein interactions, including protein binding and enzyme-substrate 
reactions. (C) Reverse-phase protein microarrays are based on the immobilization of different lysate 
samples on the same chip. (adapted from Sutandy et al. 2013) 
Functional protein microarrays 
Functional protein microarrays are used to characterize protein functionality at the proteome 
level (figure 4.1B). It has been widely used for the characterization of biochemical properties 
of proteins, such as binding activities, including protein-protein, protein-DNA, protein-lipid, 
protein-drug, and protein-peptide interactions.In addition, it has been applied to study 
enzyme-substrate relationships via different types of biochemical reactions [10] and for 
profiling protein post-translational modifications, including phosphorylation, ubiquitylation, 
acetylation, and nitrosylation [11].  
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Reverse-phase protein microarrays 
Reverse-phase microarrays are based on the immobilization of complex samples obtained at 
different time points or under various experimental conditions (figure 4.1C). By direct 
spotting of tissue, cell lysates or fractionated cell lysates it allows the simultaneous analysis 
of many different probes. This kind of array is mainly used to monitor histological changes in 
samples like cancer tissues, allowing a proteomic spatio-temporal profiling of protein 
expression or post-translational modifications.   
Protein microarrays in this thesis: configurations, limitations  and 
future perspectives 
The chapters two and three of this thesis describe analytical microarrays in which the target 
proteins were indirectly detected applying a fluorescently-labeled probe. In particular, in the 
screening applied to Staphylococcus aureus, S. aureus recombinant purified proteins were 
immobilized on the microarray chip, and this chip was tested against the test sample (human 
proteins fused with a FLAG-tag). Binding was detected using an anti-FLAG antibody and a 
secondary fluorescently labeled antibody to amplify and increase the signal. In chapter three, 
instead, human recombinant proteins were immobilized on the chip. A biotinylated Neisseria 
meningitidis protein was used as test sample and the binding was detected using 
fluorescently labeled streptavidin. The first approach has the major advantage to drastically 
amplify the signal, with the consequence of an increased detection limit, in particular for low-
affinity interactions, which usually are characterized by low MFI (mean fluorescence 
intensity) values. Despite that, the use of antibodies can constitute a source of non-specific 
or promiscuous signals requiring  an accurate setting of appropriate experimental conditions 
and a stringent negative control. In the opposite way, in the second approach the use of a 
biotinylated analyte minimized the non-specific signal, although, also in this case a dedicated 
negative control was needed. On the other hand, in this experimental setting signal 
amplification was not obtained and, in addition, direct biotinylation of the protein and the 
degree of biotinylation could contribute to modify the biological activity of the protein. Since 
known interactors that could have served as positive controls were not present among the 
immobilized proteins, it was not possible to understand if the biotinylated protein retained its 
biological function. This last drawback does not exist if, like in the case of the screening 
performed in chapter two, an antibody is used for detection, since the protein structure is not 
modified by any direct coupling procedure.  
Furthermore, in both the microarray configurations used, it is not easy to understand whether 
the immobilized proteins retain their 3D structure and activity [12]. A global check of spotting 
efficiency is usually performed as validation step, but it typically relies on antibodies directed 
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against linear epitopes or protein tags, e.g. His-tag, GST-tag (Glutathione S-transferase) and 
Flag-tag. To avoid this issue, in the last years, derivatized surfaces were used to immobilize 
proteins in an oriented way. Instead of a common adsorption procedure on nitrocellulose or 
PVDF (Polyvinylidene difluoride) coated chips, the affinity-based capture exploits the use of 
different tags like His-tag, GST-tag or streptavidin-tag at the N- or C-terminus of a protein to 
avoid direct immobilization on nitrocellulose and to preserve, at least in principle, its 3D 
conformation. Since the protein orientation can dramatically influence a given interaction, the 
part involved in binding may be buried, preventing the protein partner to interact. Thus, both 
the N- and C-terminal tagged protein versions should be produced to obtain reliable results.  
Protein microarray constitutes a very powerful large scale tool for PPI discovery and the 
amount of data generated with a single experiment is very high, since several hundreds of 
interactions can be found with a screening. Despite that, the approaches used in this work 
and the previously described microarrays formats do not allow the identification of very low 
affinity interactions (i.e. micromolar interactions). In nature, indeed, many protein-protein 
interactions are weak yet biologically meaningful. Recently, an avidity-based approach 
(AVEXIS - Avidity based extracellular interaction screening) was developed to fill this gap. 
Through the forced pentamerization of the proteins to be assessed, it has been possible to 
increase their affinity for the immobilized ones, thus allowing the identification of low affinity 
interactions [13, 14]. This approach constitutes a great breakthrough in the identification of 
novel PPIs. 
Validation technologies 
Downstream of a large scale screening approach that resulted in identification of novel 
protein-protein interactions, a validation process is necessary to confirm and characterize 
these interactions. In the case of PPI, validation methods usually are classified by two main 
categories: label-based and label-free technologies. While the label-based systems rely on 
the use of chemical modifications such as sequence tags, biotinylation, or fluorescent 
chromophores, the label-free detection techniques measure a physical property of the 
protein, such as mass, dielectric or optical properties that changes in the course of the 
interaction. Whereas label-based techniques provide a relatively simple, rapid and cost 
effective detection method, label-free approaches are more preferred since they offer higher 
sensitivity and real-time kinetic data. In addition, the detection without the interference of any 
labeling agent is an advantage since in principle should ensure proper protein folding and 
functionality. Label-free approaches indeed rely on the measurement of an intrinsic property 
of the query molecule without the use of any label. The limitations posed by the label-based 
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detection strategies have increased the interest in label-free approaches which are 
overcoming the limitations intrinsic to label-based approaches. 
SPR (Surface Plasmon Resonance) 
Surface plasmon resonance (SPR) is a label-free technique that allows to measure 
biomolecular interactions real-time and with very high sensitivity. In addition it allows the 
direct and rapid determination of association (kass or kon) and dissociation (kdis or koff) rates of 
a binding process, the determination of the strength of the binding and the specificity of 
interactions [15]. It is based on the creation of surface plasmons, which are oscillations of 
free electrons that propagate parallel to a metal/dielectric interface. The conventional SPR 
technique requires one binding component (the ligand) to be immobilized on a sensor chip 
whilst the other binding component in solution (the analyte) is flowed over the sensor 
surface. Signal obtained from SPR is derived from the measure of changes in refractive 
index in the proximity of  the sensor surface [16]. Any adsorption or desorption of molecules, 
therefore any binding close to the biosensor surface, is reflected in the sensorgram by a 
change in the reflection intensity with respect to the incident angle (Figure 4.2).  
 
Figure 4.2 Surface plasmon resonance (SPR) principle. SPR detects changes in the refractive 
index in the immediate vicinity of the surface layer of a sensor chip. The SPR signal is dependent on 
the mass of material at the surface. (adapted from Cooper, 2002, Nature Reviews Drug Discovery 1, 
515-528) 
The most popular SPR instrument is BiaCore (Ge Healthcare), which is considered the gold 
standard for binary PPI validation and characterization. It relies on gold layer based sensor 
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chips, usually derivatized with a wide variety of different chemicals or compounds (e.g. 
carboxymethyl dextran, streptavidin, or functionalized with several different kinds of 
antibodies) by which the ligand protein is immobilized or captured. Depending on the type of 
sensor chip, the immobilization procedure may change. The sensor chip is inserted in the 
instrument and coupled to  to a microfluidic-based system where the flow cells (usually four) 
are formed and onto which the analyte sample is injected. A real-time signal measured in RU 
(Response Units) is the output for the binding. The great sensitivity allows not only the 
characterization of very weak interactions but also it permits the study of protein-small 
molecule interactions. Despite the broad range of applications it requires a deep instrumental 
knowledge and good experimental settings to achieve the best results, since several 
parameters like the immobilization threshold and regeneration conditions are critical for 
correct data generation and interpretation. 
BioLayer Interferometry (BLI) 
Recently, BLI (BioLayer Interferometry), a novel optical technique, has been developed by 
ForteBio under the name of the “Octet” system for PPI validation and screening. BLI is an 
optical analytical method that measures interference patterns formed by light waves. Central 
component of the device is a biosensor tip, through which white light is passed. Light is 
reflected from each of the two ends of the tip and, depending on the distance between these 
ends, the reflected beams interfere constructively or destructively at different wavelengths in 
the spectrum. The interference pattern is then detected by a CCD array detector.  
The binding of molecules to the tip forms a layer that increases in thickness as more and 
more target molecules bind to the surface. As the thickness at the tip grows, the effective 
distance between the two reflective layers increases, creating a shift in the interference 
pattern formed by the reflected light. The spectral-intensity maximum of the reflected light 
changes as a function of the optical thickness of the molecular layer. Consequently, any 
change in the number of molecules bound to the biosensor tip causes a shift of the spectral 
maximum (Δλ expressed in nanometers or nm) that can be measured in real-time and 
reported as a sensorgram (figure 4.3). Thus, a change in optical mass thickness of 1 nm 
results in a 1 nm shift in the interferometry wave pattern. According to this principle, 
association is detected as a positive shift caused by the increase in thickness of the layer, 
while dissociation is correlated with a negative shift, thus providing the basics for binding 
kinetics calculation [17].  
Similarly to SPR, the analysis of biomolecular interactions starts with the immobilization of a 
ligand on the biosensor surface. Also in this case a wide variety of tips with different surface 
chemistries are available on the market. The ligand-bearing tip, previously blocked against 
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non-specific binding (if needed), is then used to monitor direct interactions with an analyte 
diluted in a buffer solution. The real-time signal in this case is expressed as a nanometer 
shift. The absence of microfluidics or flow cells permits also the direct use of crude samples 
like cell extracts or sera. In addition, the possibility to screen in simultaneously 8 or 16 tips 
(depending on the instrument type) allows for the screening of different samples or working 
conditions very easily and in short time. This configuration allows also for working with 
regeneration-sensitive samples. Furthermore, the user friendly software allows for easier 
experimental design in comparison with BiaCore. Nevertheless, due to its physical principle 
itself, the sensor tips are characterized by a two-dimensional surface, therefore loosing the 
advantages provided by dextran-coated matrixes used in SPR and SPRi instruments. In 
addition, the instrument sensitivity is lower as compared with SPR, resulting in certain 
limitations for its experimental use. 
 
Figure 4.3 BLI working principle. White light is run through the biosensor tip producing constructive 
and destructive waves (left panel). Unbound molecules and changes in the refractive index of the 
medium do not affect the interference pattern. The wavelength shift (Δλ) is a direct measure of the 
change in thickness of the biological layer (central panel). Wavelength shift is plotted against time to 
have BLI sensograms (right panel) (adapted from Pall-Fortebio website - 
http://www.fortebio.com/octet-platform.html)  
SPRi 
In the last years, the need of a faster, more sensitive and higher throughput screening 
technology has driven the development of hybrid instruments that can merge sensitivity and 
real-time data acquisition of label-free technologies with the high throughput of screening 
technologies like protein microarrays. This is the case of SPRi (Surface Plasmon Resonance 
imaging - Horiba), an SPR-based instrument with a medium throughput. The SPRi 
instrument’s working principle is indeed very similar to that of the BiaCore, since it is based 
on an SPR detection system with a sensor chip on which ligand proteins are immobilized and 
a flow cell though which the analyte protein is injected. The medium-throughput of this 
instrument derives from the protein immobilization procedure. While in common SPR 
instruments the ligand is occupying the entire flow cell, in SPRi the ligand proteins are 
spotted in a microarray-like manner. The surface chemistry of the SPRi sensor chip is usually 
characterized by gold surface derivatization using similar reagents as conventional SPR. The 
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result is a double advantage of identifying and characterizing interactions between an analyte 
and hundreds of ligand proteins simultaneously. Furthermore, the charge-coupled device 
(CCD) camera present in the instrument is able to reconstruct an instantaneous image of the 
flow cell showing the real-time binding between a ligand spot and the analyte protein (figure 
4.4). Protein binding to the ligand spot increases the refractive index close to the surface and 
changes the fraction of light reflected at that spot, thus generating the SPR signal. 
 
Figure 4.4 The design of an SPRi binding assay. Proteins are spotted in a microarray format on 
gold-covered- glass slides. Analyte protein is tested simultaneously against all the immobilized 
proteins. An SPR sensorgram is generated for each protein spot (right panel). In addition, a visual 
reconstruction of the array is produced. (adapted from Lausted et al 2008 Mol. Cell. Proteomics) 
Despite the many advantages that this technique provides, several cons need to be 
considered. First, while protein microarray slides are in mostly disposable, meaning that only 
one analyte protein is tested on a given slide, SPRi slides can be regenerated. This may 
constitute an important additional value in terms of time and costs for ligands with similar 
properties (e.g. a panel of antibodies). Nevertheless, since regeneration conditions can vary 
a lot between different ligand proteins, it may be difficult or impossible to find a common 
regeneration setting for ligands with differing or unknown behavior, allowing for complete 
dissociation of the ligand without damaging the immobilized proteins. 
Final considerations 
Protein-protein interaction discovery and characterization is becoming more and more 
simplified thanks to a broad range of techniques and instruments specifically developed for 
this purpose. Of course each method has its own pros and cons, but in a more general view 
it is possible to summarize some positive features and negative issues that accompany these 
techniques. When dealing with PPI, in fact it is worth to keep in mind some general aspects 
that arise during the experimental procedure: 
 All the techniques presented in this chapter rely on the immobilization of one of the 
two putative binding partners; the immobilization procedure whether it is covalent, 
affinity-based (like in case of biotin streptavidin or antibody-based immobilization) or 
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diffusion-based (like in case of nitrocellulose for protein array) can contribute to the 
loss of the native 3D structure of the protein or to its false orientation. This aspect can 
dramatically and irreversibly influence the binding properties of the ligand, resulting in 
false negative results. In most cases, especially when validating with label-free 
technique a binary interaction, both the interaction partners should be used both as 
ligand and analyte, in particular if the immobilization procedure mask a part of the 
protein involved in the binding (e.g. a protein immobilized though amine coupling in 
which a patch of lysines  are involved in the binding). This is often impossible in large-
scale screening like in the case of protein microarray, but it is the price to pay in high-
throughput methods. Oriented capture using protein tag can partially solve this 
problem. However, it brings as a drawback the need for even larger number of protein 
constructs, since for a complete dataset for each protein to be tested, two versions, 
tagged either at the N or the C-terminus, would be required. 
 Similar considerations need to be made also for regeneration procedures, which are 
based on the use of low pH, high ionic strength or detergents. These compounds can 
indeed alter the protein folding, thus modifying the response to the binding partner. 
For this reason it is important to screen an extended set of possible regeneration 
conditions, trying to find those that even after repeated exposure to the regenerating 
agent do not change the original binding properties of the molecule under 
investigation This aspect is crucial for SPR and SPRi, with the limitations already 
described, while it can be overcome in protein microarray and BLI. 
 Protein folding and retained functionality can also be modified by direct coupling of 
labels. Label-based methods, which requires direct labelling of one of the two protein 
partners, have indeed the great disadvantage of relying on a label for the detection. 
The presence of fluorescent labels or biotin in the binding site, for example, can 
interfere with the binding between the two proteins. It is therefore not easy to 
understand if and how labelling procedure would influence the binding. This drawback 
can be overcome thanks to the use of secondary dyes (like labelled secondary 
antibodies) in order to prevent direct labelling of one of the binding partners. 
 When dealing with PPI screening and validation, is very important to keep in mind the 
detection limit (in terms of binding affinity) of the technique used for the assay. This 
consideration is important for both protein microarrays and label-free technologies. 
Protein microarrays used with purified proteins as both ligand and analyte, have 
indeed an important detection limit defect. All the usual detection procedures lead to 
a partial (in most of cases even total) loss of the low affinity interactions, since 
repeated washes during these procedures usually disrupt such a kind of binding 
between two proteins. This drawback may result in a large number of false negative 
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combinations, meaning that also known low-affinity interactions might not be detected 
under certain conditions in a protein microarray screening. This disadvantage is 
absent in SPR, BLI and SPRi, since real-time measurements and the absence of 
washes procedures allow to monitor and characterize also low-affinity interactions.  
 An additional important quality to take in consideration is the sensitivity, in terms of 
mass of analyte protein needed to identify the interaction. In the case of protein 
microarray, this is strictly related to binding affinity, since the higher the affinity, the 
higher the mass of analyte protein will be retained on the spot. In the case of label-
free techniques, sensitivity is a crucial parameter for the investigation of interactions 
involving low MW proteins or peptides.  
 A final note considering the preparations upstream of screening and PPI 
characterization, is on sample preparation and purity. It is quite obvious that for a 
large scale screening, the purer the protein samples are, the less artefacts, 
background noise or false positives can arise. With the development of cutting-edge 
instrumentation in high-throughput protein expression and purification, the quality of 
the protein used in large scale screening is steadily increasing, bringing also a higher 
quality and confidence for the data generated. Less obvious, instead, are 
considerations on sample quality used for most label-free techniques. In this case, 
sample quality is not only referring to possible contaminations from heterologous 
proteins, but also from different oligomeric or even aggregated forms of the protein 
itself. For a correct data interpretation and binding analysis, it is indeed fundamental 
to use the most homogeneous and well characterized samples available in order to 
minimize misleading results. 
In summary, when dealing with PPIs discovery and validation, it is worth to keep in mind 
the fragile and susceptible structure of the proteins. Thus, it is important, while setting up 
the experimental conditions, to choose the one that implies a minimum of protein 
modification and the most native conditions. Furthermore, since each method has its own 
advantages and disadvantages, it is recommended to validate the interaction with at least 
two different techniques to obtain the most reliable results.   
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Discussion and conclusions 
Thousands years of host and pathogen co-evolution have driven to the development of fine 
mechanisms for pathogen clearance and astute effectors for bacterial survival within the 
host. Every day, within the host field, a real molecular battle between the hosts' and 
pathogen's molecular arsenals take place and a precarious balance between the two armies 
lie beneath pathogenesis or health. Thus, a wide variety of host-pathogen interactions occur 
giving rise to a global cross-talk between the two components. The vast majority of these 
interactions take place between the host and pathogen extracellular effectors, namely the 
extracellular proteomes, constituted by all the proteins secreted or surface exposed by the 
cells. From human side, typical effectors are proteins constituting the innate immune system, 
like the complement proteins and antimicrobial peptides, the first lines of human defense. 
Complement system is indeed characterized by a cascade of proteolytic events involving 
more than 30 proteins which are activated by non-self stimuli [1-3]. Three main pathway have 
been described, each of it recognizing specific non-self molecules. The complement classical 
pathway recognizes mainly aggregated antibodies on bacterial/viral surfaces, the 
complement lectin pathway recognizes carbohydrates on bacterial surface while alternative 
pathway is self-activating. All the pathways converge in the central cleavage of complement 
component C3 driving to bacterial opsonization, phagocytosis and direct killing thanks to 
membrane attack complex (MAC) formation. During cascade activation pro-inflammatory 
products (anaphylatoxins) are produced leading to cell mediated immune response 
activation. Pathogenic bacteria and viruses have evolved several mechanisms to adhere to 
host cells, penetrate, elude the immune system and spread throughout the host body. In the 
recent years a more detailed but still incomplete understanding of the molecular mechanisms 
which underlie bacterial pathogenesis has started to grow. Plenty of examples are present in 
literature and the knowledge is spreading widely through the main pathogenic bacteria [4-8]. 
Staphylococcus aureus and Neisseria meningitidis constitutes two peculiar examples. 
S.aureus has widely been described as the master in immune evasion, since it possess a 
plethora of proteins identified to specifically target host immune components. In particular 
extensive literature is present on its ability in complement evasion [9, 10]. Several S. aureus 
proteins can indeed bind complement proteins and complement receptors therefore impairing 
the first line in immune response. N. meningitidis, in a similar way, has been described to be 
able to recruit complement regulators consequently resulting complement down-regulation 
and inhibition [11-13]. Bacteria take advantage of the common structural features of 
complement regulators to broaden the number of human protein targeted; it is not 
uncommon, indeed, that a single bacterial protein targets multiple host proteins with common 
structural features. All the studies has led to the identification of three main mechanism of 
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complement activation: the recruitment or mimicking of complement regulators, the 
inactivation by enzymatic degradation (proteolysis) and the modulation or inhibition of 
complement proteins by direct interactions [14-20]. 
Despite the large variety of examples already described, a deeper knowledge in mechanisms 
that underlie bacterial pathogenesis and immune evasion is essential for therapeutic 
purposes. Bacterial immune evasion molecules and all the surface-exposed molecules that 
can be target for complement activating or neutralizing antibodies constitutes indeed 
excellent vaccine antigens. Capsular polysaccharides from pneumococcus and 
meningococcus, for example, are part of effective licensed vaccines [21]. Furthermore, factor 
H binding protein (fHbp) from N. meningitidis, a protein involved in complement factor H 
binding and deregulation of complement activity within the host, is part of the recently 
released 4 components vaccine against type B meningococcus (4cMenB) [22-24]. Antibodies 
elicited against fHbp act both mediating direct bacterial lysis through classical complement 
pathway activation, and preventing binding of fHbp to complement factor H thereby 
increasing bacterial susceptibility to complement [25-27]. The large number of interactions 
discovered so far, sometimes promiscuous and involving multiple components of the human 
defense apparatus, seems to suggest a very complex picture where additional interactions 
may take place at the host-pathogen interface. In this study an un-biased systematic large 
scale protein microarray-based approach was used to indentify novel interactions between 
the human and the S. aureus extracellular proteomes. The same approach was used to 
identify novel potential receptors for the Neisseria adhesin A (NadA), part of the 4CMenB 
vaccine and key determinant of mengicoccal interactions with the human host at different 
stages of infection.  
In chapter two, S. aureus proteins predicted from bioinformatic analysis to be surface 
exposed or secreted were efficiently cloned, expressed and purified in high-throughput way. 
The 159 purified proteins (108 as single constructs and 10 as multiple constructs), among 
which known virulence factors were present, were spotted on nitrocellulose coated slides 
together with internal and positive controls. The immobilization of the S. aureus proteins on 
the chip was confirmed by preliminary validation experiments. The resulting microarray chips 
were tested using 75 human recombinant proteins selected from a larger library [28]. Among 
the human proteins several complement factors, complement receptors and coagulation 
factors and receptors were present. The screening resulted in a total of 11766 combinations 
between pairs of human and S. aureus proteins. Among these, as expected, only a small 
proportion (<5%) gave a positive signal for interactions and, in particular, 457 (4%) putative 
interactions have been detected with a low signal, 42 (0,36%) with a medium and 19 (0,16%) 
with a highly reactive one, on the basis of their normalized MFI values. The appropriate 
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incubation conditions developed for the screening, the correct thresholds set for the analysis 
and the integrity of the bacterial and human proteins were confirmed by the positive controls 
constituted by fHbp, which showed high MFI values when incubated with complement factor 
H. This large scale approach led also to the identification and exclusion from analysis of non-
specific interactions. Human ficolin 2 and staphylococcal protein A, for example, were non-
specifically reactive with several proteins and could be easily recognized. Interestingly, the 
17 hits (19 minus the positive controls) found in the array were shared between LytM, a 
staphylococcal autolysin previously shown to be an important regulator of S. aureus cell 
cycle and cell wall turnover [29], Csa1D, member of the Conserved Staphylococcal Antigen 
family described as a promising vaccine antigen in Schluepen et al 2013 [30] and FLIPr, 
previously described as potent inhibitor of formyl-peptide receptors and FcγR antagonist [31, 
32]. This last protein was found to interact, potentially strongly based on the detected signals, 
with six different human proteins: the intercellular adhesion molecule 5 (ICAM5), the heat 
stable enterotoxin receptor (GUCY2C), the complement component 1q subcomponent like 4 
(C1QL4), the matrix remodelling associated protein 8 (MXRA8), the complement component 
1q subcomponent B (C1QB) and the bone sialoprotein 2 (IBSP). All the potential interactions 
found might be interesting for their relevance in the different steps of pathogenesis, but 
further work is currently needed to prove and underline their functional and biological 
relevance. On the other hand, a closer analysis of the human proteins reactive with FLIPr, to 
a lesser, but still significant extent, revealed additional potential interactors among which the 
complement component 1q subcomponent A (C1QA), the complement component 1q 
subcomponent like 2 (C1QL2) and the complement component 1q subcomponent C (C1QC - 
MFI 8302) constituted potentially remarkable hits for further validation and characterization 
since involved key players of the offense/defence mechanism. The interaction between FLIPr 
and the C1qA, C1qB and C1qC subcomponents was validated through the use of BLI 
(BioLayer Interferometry). The analysis showed low nanomolar affinity, meaning of a high 
affinity interaction, as also expected from MFI (Mean Fluorescent Intensity) signals showed 
by protein microarray. A direct correlation between MFI signals and interaction affinity was 
indeed previously described [33, 34]. Since in serum the three C1q subcomponents complex 
together to form the C1q complex, additional binding experiments were performed using C1q 
complex purified from human serum. The resulting affinity changed in order to the 
immobilized protein. A low picomolar affinity was measured when FLIPr was immobilized, 
while high nanomolar affinity was measured when C1q was immobilized. The reason of this 
discrepancy is still unclear and was not deeply investigated, but in our hypothesis, since the 
C1q complex possess possibly multiple binding sites for FLIPr, it is probably caused by an 
avidity effect of the C1q complex when FLIPr is immobilized, as also previously shown for 
other bacterial C1q-binding protein [35]. In order to have the biological affinity constant of the 
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complex, an in-solution technique (e.g ITC) should be used. Nevertheless, this type of 
technique is avid of protein, and a lot of additional work should be needed to provide the 
material necessary for the experiment. Additional in vitro assays provided functional 
information on this protein complex and confirmed the importance of FLIPr in bacterial 
pathogenesis. FLIPr was indeed able to significantly reduce the complement classical 
pathway activation in vitro in WiELISA experiment. Despite this result, it is not yet clear if 
FLIPr directly prevent complement activation or whether it activates complement, leading to 
consumption of the complement proteins and thus resulting in a lower complement activation 
in the assay, as also previously described for others bacterial proteins [36]. Even though 
complement inhibition and deregulation is the main mechanism in immune evasion, there are 
increasing evidences that some pathogens (in particular viruses) actively induce complement 
activity [4, 37]. A fine balance between complement inhibition and activation is indeed used 
by pathogens to prevent killing on one side, and favour phagocytosis on the other. The FLIPr 
pro-evasion properties were also confirmed by whole blood assay, in which the addition of 
FLIPr resulted in dramatically higher S. aureus in vitro survival. In this work FLIPr is 
described for the first time as a C1q-binder and complement inhibitor protein, while in 
literature several works described FLIPr as an inhibitor of the FcγR, a phagocytosis activator 
[31, 32]. Combining the data present in literature and the functional data obtained in this work 
an "affinity driven model" was presented. In this model when S. aureus faces low serum 
environment (e.g. interstitial space), FLIPr preferentially binds FcγR to inhibit neutrophil 
mediated phagocytosis. When S. aureus is instead exposed to high serum environment (e.g. 
blood) preferentially binds C1q. This can result in both complement inhibition, resulting in 
FcγR mediated phagocytosis or in complement activation, resulting as well in complement 
mediated phagocytosis. In this model S. aureus might selectively promote phagocytosis 
when it deals with unfavorable environment conditions (complement pressure), preferring an 
intracellular lifestyle in neutrophils instead of bloodstream. This model can also represent a 
good proof of concept for the Trojan horse theorized by Thwaites et al. [38] for which 
neutrophils represent a privileged site for S. aureus in the bloodstream, offers protection from 
most antibiotics and provides a mechanism by which the bacterium can travel to and infect 
distant sites.  
The same large scale approach, was also used in chapter three to identify potential novel 
receptor for NadA. In this case, instead, the whole human library constituted by ~2700 
human recombinant proteins was spotted on slides. NadA variant 3 (NadA3) was tested in 
overlay at two concentrations and lead to the identification of several human putative 
interactors. The hits resulted from the screening using NadA3 at 150nM were two isoforms of 
the VIP (Vasoactive Intestinal Peptides), LOX-1 (low-density oxidized lipoprotein lectin-like 
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receptor 1) and PTPRS (Protein Tyrosine Phosphatase Receptor type Sigma isoform 4). All 
these proteins have been previously described to be involved in bacterial pathogenesis [39-
48]. STIM1 (Stromal interaction molecule 1 precursor), NPPC (Natriuretic Peptide Precursor 
C), the hypothetical protein LOC122258 precursor and IL-6 (Interleukin 6 precursor) were 
instead revealed only in the screening performed at 1µm, possibly meaning a lower affinity 
for NadA if compared to the previous hits, which were all confirmed also in this second 
screening. As well, for all of them except for the hypothetical protein LOC122258, an 
implication in bacterial pathogenesis has been previously described [49-59]. Despite the 
identification of such a large number of hits, is it possible that many of the protein-protein 
interaction are weak in nature yet biologically meaningful. Moreover, there is no guarantee all 
proteins retain their secondary and tertiary structure when immobilized or their biological 
activity. 
Within the identified hits, LOX-1, the receptor for oxidized low-density lipoproteins, 
constituted a potentially remarkable hit for further characterization since it was the only 
endothelial receptor identified in the screening. In addition, the interaction between NadA3 
and an endothelial receptor was never described before and it can constitute a key feature in 
the understanding of N. meningitidis pathogenesis. Binding experiments using BLI confirmed 
the interaction between NadA3 and LOX-1 showing an affinity of ~60nM constant in both the 
binding orientations. This data was also confirmed by dynamic light scattering (DLS) analysis 
which showed the complex is formed also in solution. The hydrodynamic radius and the 
calculated MW of both NadA3, LOX-1 and the complex is actually much larger than the 
expected based on calculations carried out on globular proteins. This discrepancy can be 
easily explained by the rod-shaped structure of the proteins as well as, for the NadA3-LOX-1 
complex, by the possible head-to-head interaction, as also suggested by the constructs 
tested in BLI. Indeed further experiments carried out using NadA3 stalk (91-342) and 
head&neck (24-170) constructs identified the latter as the major binding region. Affinity 
constant measurement of the NadA324-170 construct on LOX-1 revealed an affinity much 
higher than the full-length protein. This effect was not investigated further, however it seems 
to suggest that the decreased steric hindrance of NadA324-170 construct compared to 
NadA324-342 leads to a faster accessibility of LOX-1 for the ligand. The identification of NadA3 
head as the binding region for LOX-1 was also confirmed by competition experiments using 
anti-NadA3 mAbs. All the tested mAbs targeting NadA3 head (24-170) showed competition 
with LOX-1 for NadA binding, while the mAb 9F11 mapping on NadA stalk (269-316) showed 
higher binding intensity if compared with NadA3 alone. This effect is probably due to an 
increased mass of NadA3 complexed with 9F11 which results in higher interference, and 
thus in higher signal in BLI. The binding between LOX-1 and NadA3 was further corroborated 
by cellular binding assay. Despite the low level of LOX-1 transfection (32.9%), all the CHO 
 xx 
 
cells transiently expressing LOX-1 showed binding with recombinant NadA3, confirming the 
binding happens also on cell surface. 
The identification and biophysical validation of an endothelial receptor, among the others, for 
NadA3 constitutes an additional value for the understanding of N. meningitidis pathogenesis. 
NadA was indeed always showed to bind receptors on monocytes and epithelial cells in vitro 
[60, 61]. Further studies will be necessary to clarify NadA role in endothelium binding, in 
order to understand if it can contribute in endothelial crossing, being for this reason 
responsible in crucial mechanisms like blood-brain barrier crossing and meningitis 
development. 
This work has widely demonstrated that protein microarray constitutes an un-biased powerful 
large scale tool for discovery of novel host-pathogen interactions. Despite the need of large 
libraries to be expensively (in terms of money, resources and time) produced for the 
screening, the amount of data generated over time with such approach can easily 
compensate for material preparation. In addition, being a "non-hypothesis-driven" approach, 
it prevents hypothesis-based bias in the investigation of an interaction mechanism. Of 
course, as a drawback, a deep statistical analysis or, like in the case of this work and as well 
as for other screening techniques, a downstream lab-based validation is needed to confirm 
the validity of the identified hits. Despite that, in this work protein microarray was confirmed 
to be a very reliable method, since the two out of two hits investigated more deeply were also 
confirmed by downstream analysis.  
In summary, this work hopefully contributed in the understanding of a precise molecular 
mechanism that S. aureus uses for complement evasion, as well as shed light on human 
receptors targeted by N. meningitidis NadA, contributing in the understanding of molecular 
mechanisms used for pathogenesis. In addition this work possibly contributed to technical 
advances in the identification of novel host-pathogen, and widely, protein-protein 
interactions.   
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Abbreviation list 
 
4CMenB: 4 component meningococcus type B vaccine formulation 
AP: complement alternative pathway 
AR2G: Amine Reactive 2nd Generation biosensor 
BLI: Bio-Layer Interferometry 
C1q: complement component C1q 
C1qA: complement component C1q subcomponent A 
C1qB: complement component C1q subcomponent B 
C1qC: complement component C1q subcomponent C 
C1r: complement component 1r 
C1s: complement component 1s 
C2: complement component C2 
C3: complement component C3 
C4: complement component C4 
C4BP: C4 binding protein 
C5: complement component C5 
C6: complement component C6 
C7: complement component C7 
C8: complement component C8 
C9: complement component C9 
CCP: complement control protein 
CFH: complement factor H 
CFI: complement factor I 
CHIPS: chemotaxis inhibitory protein of S. aureus 
ClfA: clumping factor A 
ClfB: clumping factor B 
CP: complement classical pathway 
CPP: complement control protein  
CR1: Complement receptor type I (CD35) 
CRD: C-type carbohydrate recognition domain 
CRP: C Reactive Protein 
CTLD or CLECT: C-type lectin-like domain 
CUB: complement C1r/C1s, Uegf, Bmp1 domain 
CWA protein: Cell Wall Anchored protein 
Cy5: cyanine 5 
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DAF: decay-accelerating factor (CD55) 
DLS: Dynamic Light Scattering 
Eap: extracellular adherence protein 
Ebps: elastin-binding protein 
ECM: extracellular matrix 
EDC: 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
Efb: extracellular fibrinogen-binding protein 
EGF: epidermal growth factor  
Ehp: Efb-homologous protein  
Emp: extracellular matrix protein-binding protein 
EsxA: ESAT-6 Secretion Systems protein A 
EsxB: ESAT-6 Secretion Systems protein B 
FACS: Fluorescence -Activated Cell Sorting  
FBG: fibrinogen binding domain 
Fc: fragment crystallizable of IgG 
FcγR: fragment crystallizable gamma receptor 
fHbp: factor H binding protein 
FLIPr: formyl-peptide receptor like-1 inhibitory protein 
FLIPr- like: formyl-peptide receptor like-1 inhibitory protein - like 
FnBA: fibronectin-binding protein 
FPR: formyl-peptide receptor 
FPRL1: formyl-peptide receptor like-1 
GAS: group A Streptococcus  
GBS: group B Streptococcus 
GPCRs: G-protein coupled receptor 
GST tag: Glutathione S-transferase tag 
HDL: High Density Lipoprotein   
HEK293: human embryonic kidney cell line 
His-tag: histidine tag 
HLA: Hemo-Lysin Alpha 
hsp70: heat shock protein 70 
hsp90: heat shock protein 90 
IgG: immunoglobulin G 
IMD: Invasive meningococcal disease 
IsdA: ron-regulated surface determinant protein A 
IsdB: ron-regulated surface determinant protein B 
KD: dissociation constant 
 xxvii 
 
LOS: lipo-oligosaccharides 
LOX-1: Lectin-like Oxidized LDL receptor-1  
LP: complement lectin pathway 
LPS: lipo-polysaccharides 
LytM: Glycyl-glycine endopeptidase 
mAb: Monoclonal antibody 
MAC: membrane attack complex 
MASP: Mannan-binding lectin serine protease or mannose-associated serine protease 
MCP: membrane cofactor protein (CD46) 
MDRS: Multi Drug Resistant Strains 
MenB: Meningococcus type B 
MFI: mean fluorescence intensity 
MSCRAMMs: Microbial Surface Component Recognizing Adhesive Matrix Molecules 
Msf: meningooccal surface fibril 
MW: molecular weight 
NadA: Neisserial adhesin A 
NadA3 FL: NadA variant 3 full length protein  
NadA3: NadA variant 3 
NEAT: Near iron Transporter 
NHS: N-hydroxysuccinimide 
NspA: neisserial surface protein A,  
NspA: neisserial surface protein A 
OMV: outer membrane vesicles 
Opc: opacity protein 
oxLDL: oxidized Low Density Lipoprotein   
PAMPs: pathogen-associated molecular patterns 
PorA: porin A 
PTPRS: Protein Tyrosine Phosphatase Receptor type sigma isoform 4 
PVDF: Polyvinylidene fluoride 
RCA: regulators of complement activity 
RGD: domain: arginin- glycine-aspartic acid domain 
SA: Streptavidin biosensor 
Sbi: staphylococcal binder of immunoglobulin 
SCIN: staphylococcal complement inhibitor 
SCR : short consensus repeat  
SdrB: Serine-Aspartate Repeat containing protein B 
SdrC: Serine-Aspartate Repeat containing protein C 
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SdrD: Serine-Aspartate Repeat containing protein D 
SE-HPLC/MALLS: size exclusion- high performance liquid chromatography/multi angle laser 
light scattering 
SP domain: serine protease domain 
SpA: Staphylococcal protein A 
SSL-10: superantigen-like 10 
SSL-7: superantigen-like 7 
TAA: trimeric autotransporter adhesion 
TLR4: toll-like receptor 4 
WHB: whole human blood 
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